WO2008012952A1 - Composition for stimulation of metabolism - Google Patents

Composition for stimulation of metabolism Download PDF

Info

Publication number
WO2008012952A1
WO2008012952A1 PCT/JP2007/000804 JP2007000804W WO2008012952A1 WO 2008012952 A1 WO2008012952 A1 WO 2008012952A1 JP 2007000804 W JP2007000804 W JP 2007000804W WO 2008012952 A1 WO2008012952 A1 WO 2008012952A1
Authority
WO
WIPO (PCT)
Prior art keywords
theanine
metabolism
fatigue
promoting
composition
Prior art date
Application number
PCT/JP2007/000804
Other languages
French (fr)
Japanese (ja)
Inventor
Yoshitake Baba
Akihiro Abe
Ayumu Nozawa
Yuko Sagesaka
Takami Kakuda
Noritaka Okamura
Shojiro Tsukamoto
Taizo Kubo
Original Assignee
Ito En, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2006205967A external-priority patent/JP2008031080A/en
Priority claimed from JP2006253686A external-priority patent/JP2008074733A/en
Priority claimed from JP2006287105A external-priority patent/JP4709120B2/en
Application filed by Ito En, Ltd. filed Critical Ito En, Ltd.
Publication of WO2008012952A1 publication Critical patent/WO2008012952A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics

Definitions

  • the present invention relates to a metabolism-promoting composition containing theanine as an active ingredient, and more particularly to a metabolism-promoting composition characterized in that a metabolism-promoting action is produced by the fat utilization promoting action of theanine.
  • the present invention has the effect of promoting metabolism, improving endurance, promoting growth hormone secretion, increasing blood glucose level, fat burning, reducing fatigue during aerobic exercise, increasing anaerobic metabolic threshold, reducing blood lactate accumulation, anti-fatigue It is related with the metabolism promotion composition characterized by being, and the food / beverage which mix
  • the present invention relates to a method for promoting metabolism characterized by orally ingesting such a composition or food or drink.
  • Metabolism generally refers to a chemical reaction in a living body, and obtains energy by synthesizing a substance taken from outside the body into another substance.
  • energy metabolism primary metabolism
  • secondary metabolism secondary metabolism
  • drug metabolism etc.
  • Metabolism is known to involve processes such as anabolism and catabolism, and is involved in various actions in vivo.
  • Energy metabolism is also called central metabolism or primary metabolism. Energy metabolism involves both catabolic and catabolic reactions related to sugars, amino acids and fatty acids. On the other hand, secondary metabolism is related to the production of substances that are not involved in the central metabolic system. Drug metabolism (foreign substance metabolism) involves detoxification and detoxification of in vitro substances such as poisons and drugs. In the present invention, metabolism refers to energy metabolism or secondary metabolism, and does not include drug metabolism (foreign substance metabolism).
  • Such fatigue functions as an alarm for protecting the body and mind from excessive abuse, and is an in-vivo mechanism indispensable for maintaining a living body.
  • body fatigue functions as a vital defense system that prevents chronic fatigue and overwork death.
  • the brain senses that the body is impossible, the information is transmitted to the brain stem class body, from the brain stem class body to the hypothalamus, which is the center of the autonomic nervous system, as well as instincts such as appetite and sexual desire. It is transmitted to the limbic system that controls emotions, and further transmitted to the cerebral cortex that controls movement and the five senses, where information is analyzed and judged, and the command is transferred from the central nervous system to the autonomic nervous system, immune system, and endocrine system.
  • the information is transmitted and brings about physical changes.
  • the muscles are overworked with sports, the information is transmitted from the muscles to the brain, and the information is transmitted from the muscles to the brain, causing a feeling of fatigue, and causing muscle pain in the limbs.
  • compositions for example, isoflavones derived from soybeans (Patent Document 1), kabushinoids derived from pepper (Patent Document 2), guava leaf extract (Patent Document 3), grapes Origin of resveratrol (Patent Document 4) and the like are already known.
  • Patent Document 5 a nutrient that serves as an energy source
  • Patent Document 6 a feeling of fatigue due to the excitement effect
  • the present invention uses theanine as an active ingredient.
  • theanine has a relaxing effect (Patent Document 7) and a mental fatigue recovery effect (Patent Document 8). It is also known that theanine recovers fatigue associated with decreased blood flow (Patent Document 9).
  • Patent Document 7 a relaxing effect
  • Patent Document 8 a mental fatigue recovery effect
  • Patent Document 9 theanine recovers fatigue associated with decreased blood flow
  • Patent Document 1 Japanese Patent Application Laid-Open No. 2 0202 _ 2 0 3 0 4
  • Patent Document 2 Japanese Patent Laid-Open No. 2 0 0 4 _ 1 4 9 4 9 4
  • Patent Document 3 Japanese Patent Laid-Open No. 2 0 0 5 _ 1 3 0 0 6
  • Patent Document 4 Japanese Laid-Open Patent Publication No. 2 0 0 7 _ 1 4 5 8 0 9
  • Patent Document 5 Japanese Patent Laid-Open No. 2 0 0 5 _ 0 9 7 1 6 1
  • Patent Document 6 Japanese Patent Laid-Open No. 09-9-0 5 9 1 6 1
  • Patent Document 7 Japanese Patent Laid-Open No. 2 0 0 2 _ 3 7 0 9 7 9
  • Patent Document 8 Japanese Patent Laid-Open No. 2 0 0 5 _ 1 8 7 3 4 4
  • Patent Document 9 Japanese Patent Laid-Open No. 2 0 0 1 _ 3 1 6 2 5 6
  • Non-patent document 1 Separate volume ⁇ History of medicine, science of fatigue, 2 0 0 1
  • An object of the present invention is to provide a highly safe energy metabolism promoting composition, in particular a metabolism promoting composition in which energy metabolism is promoted by a lipid utilization promoting action, a food or drink containing the metabolism promoting composition,
  • An object of the present invention is to provide a method for promoting metabolism by orally ingesting such a metabolism promoting composition and food and drink.
  • theanine has an energy metabolism promoting action, particularly an energy metabolism promoting action by a lipid utilization promoting action, and has completed the present invention.
  • Theanine also helps to improve endurance, promote growth hormone secretion, increase blood sugar levels, burn fat, reduce fatigue during aerobic exercise, increase anaerobic metabolic threshold, reduce blood lactate accumulation, and anti-fatigue. As a result, the present invention has been completed.
  • a metabolism promoting composition comprising theanine as an active ingredient
  • Metabolism-promoting action improves endurance, promotes growth hormone secretion, increases blood glucose levels, fat burning, reduces fatigue during aerobic exercise, increases anaerobic metabolic threshold, blood lactate accumulation
  • the metabolism promoting composition according to the above (1) or (2) characterized in that it is selected from the group consisting of reducing fatigue and anti-fatigue,
  • a method for promoting metabolism comprising orally ingesting the composition for promoting metabolism according to any one of (1) to (6) above,
  • Metabolism promoting action from lipid utilization promotion, growth hormone secretion promotion, blood sugar level increase, fat burning, fatigue reduction during aerobic exercise, anaerobic metabolic threshold increase, blood lactate accumulation reduction, anti-fatigue The method of promoting metabolism according to (7) above, wherein the method is one or more selected from the group consisting of:
  • a highly safe energy metabolism promoting composition particularly a metabolism promoting composition in which energy metabolism is promoted by a lipid utilization promoting action, a food and drink containing the metabolism promoting composition, It is possible to provide a method for promoting metabolism by orally ingesting such a metabolism promoting composition or food and drink.
  • the metabolism promoting composition of the present invention can be prepared by incorporating theanine as an active ingredient. These compositions can be incorporated into foods and beverages. Such metabolism promoting compositions and foods and drinks containing the same can be prepared by adding theanine. However, compositions containing theanine, plant extracts, foods and drinks and other theanine-containing substances It can also be prepared by blending.
  • Theanine is a derivative of glutamic acid contained in green tea and the like.
  • L-glutamic acid ethylamide L-theanine
  • L-glutamic acid __ methyl amide D-glutamic acid __
  • Derivatives containing L- or D-glutamic acid mono-alkyl amides, L- or D-glutamic acid _ -alkyl amides in the basic structure eg L-amino acid (D-theanine), D-glutamic acid _ _methyl amide, etc.
  • D-glutamic acid a glycoside of ⁇ _alkyl amide, etc.
  • a mixture of one or more compounds selected from the group consisting of two or more compounds can be used.
  • L-theanine is not only obtainable from natural products, but is also recognized as a food additive, and is particularly preferred from the standpoint of availability and safety.
  • Theanine can be produced by various known methods. For example, it can be biosynthesized by a culture method of plants or microorganisms, extracted from tea leaves, fermented or chemically synthesized. Specifically, JP-A-05-068578 (paragraphs [0006]-[0021]), JP-A-5-328986 (paragraphs [0008]-[0027]), JP-A-09-263573 (paragraphs [0009]-[0029]).
  • theanine can be used alone as an active ingredient of the metabolism-promoting composition of the present invention, but can also be used by mixing with other components.
  • Theanine can also be used as a lysate in purified products, crude products, tea extract extracts, purified water or physiological saline.
  • Metabolism in the present invention generally means a chemical reaction in a living body, and refers to synthesizing another substance or obtaining energy from a substance taken from outside the body.
  • metabolism promotion refers to promotion of energy metabolism and does not include drug metabolism.
  • energy metabolism energy consumed by moving the body
  • energy consumed without moving the body and doing nothing basic metabolism.
  • the promotion of metabolism means that the promotion of metabolism is promoted by promoting the utilization of lipids of theanine which is an active ingredient.
  • improve endurance means improving endurance and suppressing fatigue in a broad sense of exercise, such as work that requires endurance and labor that requires repeated muscle work. It has the effect
  • the metabolism promoting composition in the present invention is a composition containing theanine as an active ingredient and having such an action.
  • reducing fatigue during aerobic exercise means exercise that requires endurance, such as marathon, swimming, and air mouth bicus, and further work in daily life, such as oxygen consumption in the muscles and the cardiopulmonary system. This means that the oxygen supply by the body is in an equilibrium state and has the action of reducing physical fatigue that occurs when performing so-called aerobic exercise.
  • Fatigue is generally broadly divided into physical fatigue and mental fatigue.
  • the composition of the present invention reduces physical fatigue caused by aerobic exercise, and is directly applied only to spiritual fatigue. It does not work. However, in the case of both physical fatigue and mental fatigue, it is necessary to administer the metabolism promoting composition of the present invention. Needless to say, physical fatigue can be reduced.
  • an increase in the anaerobic metabolic threshold means an increase in the value of oxygen intake at the time when lactic acid begins to accumulate in the blood in the body.
  • Lactic acid is used as a source of energy for skeletal muscle and is therefore an important recovery factor during fatigue.
  • its importance has been pointed out in the brain and heart ("Separate volume ⁇ History of medicine: Fatigue chemistry", p. 14, p. 205).
  • excessive accumulation of lactic acid in the muscle causes performance degradation by reducing muscle activity. Therefore, suppressing the accumulation of lactic acid in the muscle is important in preventing fatigue.
  • Anaerobic threshold metabolism is defined as “the value of oxygen intake at the time when lactate begins to accumulate in the blood” (“Introduction to Exercise Testing”) 1 48, 2001).
  • the anaerobic threshold metabolic value was originally proposed by Wasserman, and is currently used as a standard in exercise testing combined with breath gas analysis.
  • the metabolism promoting composition in the present invention refers to a composition containing theanine as an active ingredient and having such an action.
  • blood lactate accumulation reduction refers to an action of suppressing blood lactate accumulation, and such blood lactate accumulation reduction also includes an action of reducing blood lactate.
  • lactic acid is considered to be a factor for fatigue recovery of muscles and the like, and the efficient use of lactic acid is desirable from the viewpoint of recovery from fatigue. If this accumulation of lactic acid is suppressed, it is possible to suppress muscle activity decline and exercise more intensely. Can do.
  • growth hormone refers to a hormone secreted from GH-secreting cells in the anterior pituitary gland under the action of growth hormone-releasing hormone (GHRH) secreted from the hypothalamus.
  • GHRH growth hormone-releasing hormone
  • Growth hormone is involved in the growth of the body and controls all metabolic mechanisms in the body, such as protein synthesis, nitrogen balance, carbohydrate metabolism, fat metabolism, and calcium homeostasis.
  • Carbohydrate metabolism refers to the regulation of blood sugar levels. An excessive increase in blood glucose level is not preferable because it may cause diseases such as hyperglycemia and diabetes.
  • the metabolism-promoting progenitor composition refers to a substance that promotes the secretion of growth hormone in vivo.
  • the blood glucose level refers to the concentration of glucose in the blood.
  • the blood glucose level is adjusted to a normal value within a very narrow range by the action of insulin that lowers blood sugar and the action of glucagon that raises blood sugar under normal conditions.
  • glucose passes through the GLUT 2 or GLUT 1 transporter; it flows into S cells.
  • glucose is converted to glucose 6-phosphate by the action of glucokinase, calcium ions flow into the cell and insulin is released.
  • the fasting blood glucose level is approximately 80 _ 1 OO mg / d I, which is said to be slightly higher after meals.
  • the metabolic promoter composition refers to the blood glucose level in vivo. A substance that promotes ascent.
  • fat burning mainly refers to a body fat burning action that burns fat stored in the body, but also includes an action of suppressing fat accumulation by inhibiting fat absorption in the body. It is a waste.
  • theanine promotes the utilization of lipids in the living body, thereby obtaining body fat burning action and fat accumulation inhibiting action.
  • anti-fatigue refers to occurrence of physical fatigue, recovery of physical fatigue, and maintenance / improvement of endurance.
  • theanine promotes utilization of lipids and carbohydrates in the living body, and thus has anti-fatigue action, fatigue recovery action, endurance maintenance action, endurance improvement action, nourishing tonic The effect is obtained
  • the metabolism promoting composition of the present invention can be provided as a pharmaceutical and a quasi-drug.
  • the active ingredient can be prepared by dissolving it in purified water or physiological saline as it is.
  • a quasi-drug it is preferably provided in a form that is easy to ingest as much as possible, such as a drinking form such as a container-packed drink, or a form such as a tablet, force capsule, or granule.
  • the metabolism promoting composition of the present invention can also be added to food and drink materials.
  • food and drink are intended for beverages and foods.
  • Such foods and drinks can be provided as health foods, health drinks, foods for specified health use, functional foods. In that case, it can be prepared by adding the metabolism-promoting composition of the present invention to food materials that are usually blended to produce each food and drink. In addition, when approved as food for specified health use, etc., these foods and drinks shall contain a label indicating that they contain theanine and are used to promote metabolism. It can also be sold as a fresh food or beverage.
  • the active ingredient of the present invention may be a variety of food materials (including fruits and jelly), milk ingredients, carbonic acid, excipients (including granulating agents), diluents, or even sweeteners, flavors,
  • food materials including fruits and jelly
  • milk ingredients including carbonic acid
  • excipients including granulating agents
  • diluents or even sweeteners, flavors
  • proteins such as wheat flour, starch, sugar, fats and oils, carbohydrate raw materials, vitamins, minerals, other physiologically active ingredients, hormones, nutritional ingredients, sports drinks, fruits Beverages, tea beverages, vegetable drinks, milk beverages, alcoholic beverages, jelly beverages, carbonated beverages and other beverages, jelly, chewing gum, chocolate, ice cream, candy, biscuits and other sweets, snacks, bread, cakes, etc.
  • Starch-based processed foods, fish paste products, livestock meat products, tofu, cheese and other protein-based processed foods, miso soy sauce, dore Seasonings such as single, other supplements, fodder, can be provided in the form of various food such as Bae Ttofu one de.
  • the amount of theanine in the composition and food and drink is not particularly limited as long as it does not impair the intended effect of the present invention.
  • 0.5 mg to 5 mg of theanine per 1 kg of the body weight of the administration subject Preferably, 0.5 mg to 2 mg of theanine is administered per kg of the subject's body weight.
  • the composition of the present invention is administered to an adult and the body weight is 40 kg to 1 OO kg, it is preferable to administer 2 Omg to 50 Omg of theanine, and 20 mg to 20 Omg. More preferably, theanine is administered.
  • theanine content when it is taken as a guide for a person weighing 60 kg, it is preferable to adjust the theanine content to 3 mg to 300 Omg, and in particular, to adjust the theanine content to 3 mg to 12 Omg. Further preferred.
  • Example 1 Theanine promotes lipid utilization
  • male mouse CDF 1 (10 weeks old, 20 animals) was used.
  • Theanine was prepared by dissolving L-theanine in pure water to prepare a theanine solution.
  • the mouse was exercised for 180 minutes in a rotating basket, exercised on the mouse, rested for 5 minutes, and then 0.5 mg / kg of theanine was applied. After intraperitoneal administration, the patient was rested for 30 minutes after administration, and then spontaneously exercised again in a rotating basket for 180 minutes.
  • mice were spontaneously operated in a rotating basket for 180 minutes and subjected to exercise load on the mice, then rested for 5 minutes and then administered intraperitoneally. He rested for 30 minutes, and then moved again for 80 minutes in a rotating basket.
  • Example 2 Theanine's action to reduce body fatigue ⁇ Endurance improving action Male mice CD F 1 (6 weeks old, 4 animals) were used in the experiment.
  • L-theanine was dissolved in pure water to prepare a theanine solution with a theanine concentration of 0.05 mg / m I, and this was used as a sample.
  • theanine administration group (4 animals), after exercising for 80 minutes in a rotating basket and applying exercise to the mouse, resting for 5 minutes and then orally administering theanine 0.5 mg / kg. After the administration, the patient was rested for 30 minutes, and then spontaneously exercised again in a rotating basket for 180 minutes.
  • mice were exercised for 180 minutes in a rotating basket and subjected to exercise load, and then rested for 5 minutes, and then pure water 1 Om I / kg was orally administered. After administration, the patient was allowed to rest for 30 minutes, and then again exercised again for 180 minutes in a rotating basket.
  • mice CD F 1 Male mice CD F 1 (7 weeks old, 7 mice) were used in the experiment.
  • L-theanine was dissolved in pure water to prepare theanine solutions with theanine concentrations of 0.02 mg / ml, 0.05 mg I, 0.15 mg / ml and used as samples.
  • a self-exercising exercise was performed with a rolling basket, and exercise load was applied. After resting for 5 minutes, water was administered orally. After the administration, the patient was rested for 30 minutes, and then spontaneously exercised again in a rotating basket for 180 minutes. The number of rotations of the rotating cage during the first exercise and the number of rotations of the second time were measured.
  • the control group received water.
  • Theanine dose is about 3 at a common ratio of 0.
  • Fig. 4 shows a graph showing the number of rotation reductions for each administration group as the number of rotation reductions (times).
  • the endurance improvement effect of theanine was investigated by forced swimming test. Male mice CDF 1 (6 weeks old, 8 animals) were used in the experiment.
  • L-theanine was dissolved in pure water to prepare theanine solutions having theanine concentrations of 0.02 mg / ml, 0.05 mg / ml, and 0.15 mg / ml, and used as samples.
  • mice 8 animals in each group were used, and each mouse was fasted overnight (about 15 hours), then theanine or water was administered, and then left still for 60 minutes after After that, the test was performed using the same protocol as the above selection test, and the swimming time was measured.
  • the results are shown in FIG.
  • the doses of theanine were 0 • 2 mg / kg, 0.5 mg / kg, and 1.5 mg / kg at a common ratio of about 3.
  • Table 1 shows the initial values for each treatment group.
  • mice CD F 1 Male mice CD F 1 (6 weeks old, 5 mice) were used in the experiment.
  • L-theanine was dissolved in pure water to prepare theanine solutions with theanine concentrations of 0.05 mg / ml, 0.5 mg / ml, and 5. Omg / ml, and used as samples.
  • Test drink drinkl (placebo).
  • FIG. 9 shows AT values measured after ingestion of each test beverage for one week.
  • theanine low-dose and high-dose intake groups an increase in AT value was observed, and the exercise intensity that can be achieved by aerobic exercise increased.
  • FIG. 10 shows the blood lactate level (Delda value) before and after the multi-stage exercise test. Blood lactate levels at low and high theanine doses decreased. In recent years, it has been reported that lactic acid is an important cause of fatigue, so the decrease in lactic acid levels observed in the examples is thought to be the result of lactic acid contributing to recovery from fatigue.
  • Wistar male rats (Shizuoka experimental animals) were purchased at 7 weeks of age (approximately 250 g), preliminarily raised for one week, and then subjected to experiments.
  • the animal house is managed in a breeding room with a room temperature of 24 ⁇ 0.5 ° C, humidity of 55 ⁇ 5%, and a light / dark cycle (between 7:00 and 19:00).
  • Water and food (MF, manufactured by Oriental Yeast Co., Ltd.) ).
  • the osmotic pump (Alzet) which was fixed in the skull with dental cement and embedded in the back of the back, was inserted into the hippocampus on both sides.
  • Theanine manufactured by ITO EN was dissolved in physiological saline, filtered through a Millipore filter (Millex-GS, manufactured by Millipore), and then filled into an osmotic pump.
  • the drug concentrations were 0.1 u M 1 M and 10; UM, and physiological saline was administered as a control group.
  • the rat hippocampus was started with local theanine administration and fasted for about 36 hours from day 9. Thereafter, blood obtained by blood collection was used for analysis.
  • the blood sugar level at the time of slaughter was measured by the Medice Freeder (GR-101, TERUMO) equipped with a Medisafe chip (MS-FG25, TERUMO Co.).
  • Fig. 11 shows the results of examining the amount of growth hormone secreted in plasma
  • Fig. 12 shows the results of examining the amount of blood glucose produced.
  • Fig. 1 is a graph comparing the control exercise group (DW) and the theanine administration group (theanine) regarding the relative momentum in the lipid utilization promotion test of theanine (Example 1).
  • FIG. 2 is a graph comparing the control fatty acid group (DW) and the theanine administration group (theanine) with respect to blood fatty acid concentration in the lipid utilization promotion test for theanine (Example 1).
  • FIG. 3 Reduction of the physical fatigue of theanine ⁇
  • the number of rotation reduction (times) is a graph comparing the control administration group (water administration group) and the theanine administration group. is there.
  • FIG. 4 is a graph showing the number of reductions in rotations (times) for each administration group in the effective concentration confirmation test for theanine (Example 3).
  • FIG. 5 is a graph showing swimming time (seconds) for each administration group in the endurance improvement test (Example 4) of theanine.
  • FIG. 6 is a diagram showing an outline of an experimental procedure in the body fatigue reducing action (Example 5) of theanine.
  • FIG. 7 is a graph showing the amount of spontaneous exercise (times) for each administration group in the body fatigue alleviating action (Example 5) of theanine.
  • FIG. 9 is a diagram showing AT values measured after intake of each test beverage for one week. The AT values measured after ingestion of each test drink for 1 week are shown. An increase in AT was observed in the low and high dose theanine groups, and the exercise intensity that can be achieved with aerobic exercise increased.
  • FIG. 10 is a graph showing changes in blood lactic acid levels by a multi-stage exercise load test.
  • a treadmill was used for the exercise load.
  • a multi-stage exercise load test was conducted with a rotational speed of 0.5 km / h and a slope of 0%, and the rotational speed was increased by 0.5 km / h and the slope by 0.5% every 30 seconds. .
  • FIG. 1 1 is a diagram showing the results of examining the amount of growth hormone secreted in plasma.
  • FIG. 12 is a view showing the results of examining the secretion amount of blood glucose level.

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Disclosed is a composition for stimulating metabolism, comprising teanin as an active ingredient. Also disclosed is a beverage/food comprising the composition. Teanin has metabolism-stimulating effects including the enhancement of the lipid utilization, the stimulation of the secretion of a growth hormone, the increase in blood glucose level, the burning of fats, the alleviation of fatigue during aerobic exercises, the increase in anaerobic threshold and the reduction in blood lactate accumulation.

Description

明 細 書  Specification
代謝促進組成物  Metabolic promoting composition
技術分野  Technical field
[0001 ] 本発明は、 テアニンを有効成分とする代謝促進組成物、 特にテアニンの脂 質利用促進作用により代謝促進作用が生じることを特徴とする代謝促進組成 物に関するものである。 また本発明は、 代謝促進作用が持久力向上、 成長ホ ルモン分泌促進、 血糖値上昇、 脂肪燃焼、 有酸素運動時の疲労軽減、 嫌気性 代謝閾値の上昇、 血中乳酸蓄積の軽減、 抗疲労であることを特徴とする代謝 促進組成物やかかる組成物を配合した飲食物に関するものである。 さらに本 発明は、 かかる組成物や飲食物を経口摂取することを特徴とする代謝促進方 法に関する。  [0001] The present invention relates to a metabolism-promoting composition containing theanine as an active ingredient, and more particularly to a metabolism-promoting composition characterized in that a metabolism-promoting action is produced by the fat utilization promoting action of theanine. In addition, the present invention has the effect of promoting metabolism, improving endurance, promoting growth hormone secretion, increasing blood glucose level, fat burning, reducing fatigue during aerobic exercise, increasing anaerobic metabolic threshold, reducing blood lactate accumulation, anti-fatigue It is related with the metabolism promotion composition characterized by being, and the food / beverage which mix | blended this composition. Furthermore, the present invention relates to a method for promoting metabolism characterized by orally ingesting such a composition or food or drink.
[0002] 代謝とは、 生体内での化学反応を一般に指すものであり、 対外から体外か ら取り入れた物質を他の物質に合成することによりエネルギーを得るもので ある。 代謝には、 エネルギー代謝 (一次代謝) 、 二次代謝、 薬物代謝等が知 られており、 生命の恒常性を保っために代謝に関与するメカニズム (系) に 調和が保たれていなければならない。 また代謝には、 同化や異化などのプロ セスが関与することが知られており、 生体内での様々な作用に関与している  [0002] Metabolism generally refers to a chemical reaction in a living body, and obtains energy by synthesizing a substance taken from outside the body into another substance. As metabolism, energy metabolism (primary metabolism), secondary metabolism, drug metabolism, etc. are known, and in order to maintain homeostasis, the mechanism (system) involved in metabolism must be kept in harmony. Metabolism is known to involve processes such as anabolism and catabolism, and is involved in various actions in vivo.
[0003] エネルギー代謝は、 中央代謝又は一次代謝とも呼ばれている。 エネルギー 代謝には、 糖、 アミノ酸、 脂肪酸に関連した異化同化の両反応が関与してい る。 一方、 二次代謝とは、 中央代謝系に関与しないとされる物質の生産に関 与している。 なお、 薬物代謝 (異物代謝) には、 毒や薬等の生体外物質を分 解 -解毒したりするものである。 なお、 本発明において、 代謝とはエネルギ 一代謝や二次代謝を指すものであって、 薬物代謝 (異物代謝) を含むもので はない。 [0003] Energy metabolism is also called central metabolism or primary metabolism. Energy metabolism involves both catabolic and catabolic reactions related to sugars, amino acids and fatty acids. On the other hand, secondary metabolism is related to the production of substances that are not involved in the central metabolic system. Drug metabolism (foreign substance metabolism) involves detoxification and detoxification of in vitro substances such as poisons and drugs. In the present invention, metabolism refers to energy metabolism or secondary metabolism, and does not include drug metabolism (foreign substance metabolism).
[0004] エネルギー代謝を促進する作用を有する物質はすでに数多く知られている 。 物質によって幾分異なるが、 生体内における代謝促進には体内脂質の利用 促進作用が関与しており、 疲労軽減、 滋養強壮、 持久力向上、 血中乳酸蓄積 軽減、 脂肪燃焼等の効果が生じることがある。 またこれに伴って、 ホルモン 分泌が促進されて血糖値上昇、 疲労軽減、 滋養強壮、 持久力向上、 血中乳酸 蓄積軽減、 脂肪燃焼等の効果が生じることもある。 さらにエネルギー代謝促 進に伴って、 嫌気性代謝閾値の上昇や、 血中乳酸蓄積軽減効果が生じること もある。 [0004] Many substances having an action of promoting energy metabolism are already known. Although it varies somewhat depending on the substance, the promotion of metabolism in the living body involves the use of lipids in the body, reducing fatigue, strengthening nutrition, improving endurance, and accumulating lactic acid in blood. Effects such as reduction and fat burning may occur. Along with this, hormone secretion may be promoted, resulting in effects such as an increase in blood glucose level, fatigue reduction, nutrition tonicity, endurance improvement, blood lactate accumulation reduction, and fat burning. Furthermore, as energy metabolism is promoted, an anaerobic metabolic threshold may be increased and blood lactate accumulation may be reduced.
[0005] 特に疲労軽減に関していえば、 身体的な疲労と精神的な疲労とがあり、 一 般的に身体疲労とは、 肉体的活動による疲れとその蓄積、 エネルギーの消耗 を意味し、 精神疲労とは、 脳の働きや神経の活動による疲れを意味すると言 われている。  [0005] Especially when it comes to reducing fatigue, there are physical fatigue and mental fatigue. Generally, physical fatigue means fatigue and accumulation of physical activity, energy consumption, mental fatigue. Is said to mean fatigue due to brain activity and nerve activity.
[0006] 身体疲労と精神疲労が混在する場合も多いため、 症状等からいずれの疲労で あるかを判定できない場合も多いが、 疲労をもたらすメカニズム、 症状、 疲 労軽減のための機序などはそれぞれ異なる。 例えば身体疲労は、 眠い、 だる いなど、 どちらかというと頭がポーッとした状態になるのに対し、 精神疲労 の場合は、 むしろ神経が変に興奮してしまい、 イライラ怒りやすくなる、 眠 れない、 集中力低下といった状態となる。  [0006] Since physical fatigue and mental fatigue often coexist, it is often impossible to determine which type of fatigue is based on symptoms, but the mechanisms that cause fatigue, symptoms, mechanisms for reducing fatigue, etc. Each is different. For example, physical fatigue is sleepy, dull, and so on, but the head becomes a bit of a puff, whereas in mental fatigue, the nerves are rather excited, making it easy to get angry, sleep It will be in a state of poor concentration.
[0007] このような疲労は、 過度の酷使から身体や精神を守るためのアラームとして 機能しており、 生体維持に欠くことができない体内メカニズムである。 特に 身体疲労は、 慢性疲労や過労死させないために必要な生体防衛システムとし て機能している。 すなわち、 身体が無理していると脳が感じ取ると、 その情 報は、 脳幹綱様体へ伝えられ、 脳幹綱様体から自律神経系の中枢である視床 下部並びに、 食欲、 性欲などの本能や感情をつかさどる大脳辺縁系へ伝達さ れ、 さらに運動や五感をつかさどる大脳皮質へと伝達され、 ここで情報が分 析 -判断され、 その指令が中枢神経から自律神経、 免疫系、 内分泌系に伝達 され肉体的変化をもたらすことになる。 例えばスポーッで筋肉を酷使した場 合には、 その情報は筋肉から脳に伝達され、 その情報は筋肉から脳に伝達さ れ、 疲労感を感じさせたり、 また手足では筋肉痛等を生じさせる。  [0007] Such fatigue functions as an alarm for protecting the body and mind from excessive abuse, and is an in-vivo mechanism indispensable for maintaining a living body. In particular, body fatigue functions as a vital defense system that prevents chronic fatigue and overwork death. In other words, when the brain senses that the body is impossible, the information is transmitted to the brain stem class body, from the brain stem class body to the hypothalamus, which is the center of the autonomic nervous system, as well as instincts such as appetite and sexual desire. It is transmitted to the limbic system that controls emotions, and further transmitted to the cerebral cortex that controls movement and the five senses, where information is analyzed and judged, and the command is transferred from the central nervous system to the autonomic nervous system, immune system, and endocrine system. It is transmitted and brings about physical changes. For example, when the muscles are overworked with sports, the information is transmitted from the muscles to the brain, and the information is transmitted from the muscles to the brain, causing a feeling of fatigue, and causing muscle pain in the limbs.
[0008] 身体疲労も適度なものであれば、 休息や睡眠等により回復するが、 過度な身 体疲労や慢性的な疲労となると、 休息や睡眠だけでは回復が困難となるため 、 外部要因によって積極的に身体疲労を軽減する必要もある。 また、 身体疲 労に伴う倦怠感等の不快な感覚を除去乃至軽減することによって、 休息ゃ睡 眠がより効果的になる。 さらに、 身体疲労をより短時間で回復させることが できれば、 次の活動を疲労感なく効率的に行うことができる。 このように、 身体疲労は、 生体防衛システムとして不可欠ではあるものの、 効率的かつ簡 便に積極的に疲労回復させる必要性もある。 [0008] If physical fatigue is moderate, it can be recovered by resting or sleeping, but if excessive physical fatigue or chronic fatigue occurs, recovery is difficult only by resting or sleeping. It is also necessary to actively reduce physical fatigue due to external factors. Also, by removing or reducing unpleasant sensations such as fatigue caused by physical fatigue, sleep becomes more effective when rested. Furthermore, if physical fatigue can be recovered in a shorter time, the next activity can be performed efficiently without feeling tired. Thus, although body fatigue is indispensable as a biological defense system, there is also a need to recover fatigue efficiently and easily.
[0009] 上述のとおり、 このようなエネルギー代謝を促進する物質や組成物はこれ までに数多く知られている。 植物由来のエネルギー代謝促進物質■組成物に 限定しても、 例えば大豆由来のイソフラボン (特許文献 1 ) 、 トウガラシ由 来のカブシノィ ド (特許文献 2 ) 、 グアバ葉抽出物 (特許文献 3 ) 、 ブドウ 由来のレスべラトロール (特許文献 4 ) 等がすでに知られている。  [0009] As described above, many substances and compositions that promote such energy metabolism have been known so far. Plant-derived energy metabolism promoting substances ■ Even if limited to compositions, for example, isoflavones derived from soybeans (Patent Document 1), kabushinoids derived from pepper (Patent Document 2), guava leaf extract (Patent Document 3), grapes Origin of resveratrol (Patent Document 4) and the like are already known.
[0010] また特に、 疲労軽減に関しては、 このような身体疲労を軽減するための薬剤 や飲食物としては、 エネルギー源となる栄養素を供給するもの (特許文献 5 ) と、 興奮効果によって疲労感をマスキングするもの (特許文献 6 ) とが知 られていた。  [0010] In particular, with regard to fatigue reduction, as drugs and foods and drinks for reducing such physical fatigue, a nutrient that serves as an energy source (Patent Document 5) and a feeling of fatigue due to the excitement effect are provided. What was masked (Patent Document 6) was known.
[001 1 ] しかし、 いずれの場合も、 身体疲労を直接軽減するものではなく、 前者の場 合には、 カロリーの過剰摂取につながるおそれもあった。 また、 後者の場合 は、 マスキング効果が切れると、 さらなる疲労感に襲われるという問題を抱 えていた。 また、 長期間にわたって疲労感をマスキング効果で抑制し続ける と、 過労死等の深刻な問題に繋がり好ましくないことが近年指摘されている [001 1] However, in either case, physical fatigue was not directly reduced, and in the former case, there was a risk of excessive calorie intake. In the latter case, there was a problem that when the masking effect was cut off, the tiredness was further increased. In addition, it has recently been pointed out that continuing to suppress fatigue with the masking effect over a long period of time can lead to serious problems such as death from overwork.
(非特許文献 1 ) (Non-Patent Document 1)
[0012] ちなみに本発明は、 後述するように、 テアニンを有効成分とするものであ るが、 従来、 テアニンには、 リラックス効果 (特許文献 7 ) や精神疲労回復 効果 (特許文献 8 ) があることが知られており、 またテアニンが血流低下に 伴う疲労を回復することも知られている (特許文献 9 ) 。 しかし、 テアニン がエネルギー代謝促進作用、 特に脂質利用促進作用によりエネルギー代謝促 進作用を生じさせることはこれまでに報告がなかつた。  Incidentally, as described later, the present invention uses theanine as an active ingredient. Conventionally, theanine has a relaxing effect (Patent Document 7) and a mental fatigue recovery effect (Patent Document 8). It is also known that theanine recovers fatigue associated with decreased blood flow (Patent Document 9). However, it has not been reported so far that theanine produces an energy metabolism promoting effect by promoting energy metabolism, particularly lipid utilization promoting action.
[0013] 特許文献 1 :特開 2 0 0 2 _ 2 0 3 0 4号公報 特許文献 2:特開 2 0 0 4 _ 1 4 9 4 9 4号公報 Patent Document 1: Japanese Patent Application Laid-Open No. 2 0202 _ 2 0 3 0 4 Patent Document 2: Japanese Patent Laid-Open No. 2 0 0 4 _ 1 4 9 4 9 4
特許文献 3:特開 2 0 0 5 _ 1 3 0 0 6号公報  Patent Document 3: Japanese Patent Laid-Open No. 2 0 0 5 _ 1 3 0 0 6
特許文献 4:特開 2 0 0 7 _ 1 4 5 8 0 9号公報  Patent Document 4: Japanese Laid-Open Patent Publication No. 2 0 0 7 _ 1 4 5 8 0 9
特許文献 5:特開 2 0 0 5 _ 0 9 7 1 6 1号公報  Patent Document 5: Japanese Patent Laid-Open No. 2 0 0 5 _ 0 9 7 1 6 1
特許文献 6:特開平 0 9— 0 5 9 1 6 1号公報  Patent Document 6: Japanese Patent Laid-Open No. 09-9-0 5 9 1 6 1
特許文献 7:特開 2 0 0 2 _ 3 7 0 9 7 9号公報  Patent Document 7: Japanese Patent Laid-Open No. 2 0 0 2 _ 3 7 0 9 7 9
特許文献 8:特開 2 0 0 5 _ 1 8 7 3 4 4号公報  Patent Document 8: Japanese Patent Laid-Open No. 2 0 0 5 _ 1 8 7 3 4 4
特許文献 9:特開 2 0 0 1 _ 3 1 6 2 5 6号公報  Patent Document 9: Japanese Patent Laid-Open No. 2 0 0 1 _ 3 1 6 2 5 6
非特許文献 1 :別冊■医学のあゆみ、 疲労の科学、 2 0 0 1  Non-patent document 1: Separate volume ■ History of medicine, science of fatigue, 2 0 0 1
発明の開示  Disclosure of the invention
発明が解決しょうとする課題  Problems to be solved by the invention
[0014] 本発明の目的は、 安全性の高いエネルギー代謝促進組成物、 特に脂質利用促 進作用によりエネルギー代謝促進が生じる代謝促進組成物や、 該代謝促進組 成物を配合した飲食物や、 かかる代謝促進組成物や飲食物を経口摂取するこ とによる代謝促進方法を提供することにある。  [0014] An object of the present invention is to provide a highly safe energy metabolism promoting composition, in particular a metabolism promoting composition in which energy metabolism is promoted by a lipid utilization promoting action, a food or drink containing the metabolism promoting composition, An object of the present invention is to provide a method for promoting metabolism by orally ingesting such a metabolism promoting composition and food and drink.
課題を解決するための手段  Means for solving the problem
[0015] 本発明者らは、 テアニンが、 エネルギー代謝促進作用、 特に脂質利用促進作 用によるエネルギー代謝促進作用を有することを見出し、 本発明を完成する に至った。 また、 テアニンが、 持久力向上、 成長ホルモン分泌促進、 血糖値 上昇、 脂肪燃焼、 有酸素運動時の疲労軽減、 嫌気性代謝閾値の上昇、 血中乳 酸蓄積の軽減、 抗疲労の各作用を示すことを見出し、 本発明を完成するに至 つた。  [0015] The present inventors have found that theanine has an energy metabolism promoting action, particularly an energy metabolism promoting action by a lipid utilization promoting action, and has completed the present invention. Theanine also helps to improve endurance, promote growth hormone secretion, increase blood sugar levels, burn fat, reduce fatigue during aerobic exercise, increase anaerobic metabolic threshold, reduce blood lactate accumulation, and anti-fatigue. As a result, the present invention has been completed.
[001 6] すなわち本発明は、  [001 6] That is, the present invention provides:
( 1 ) テアニンを有効成分とする代謝促進組成物、  (1) A metabolism promoting composition comprising theanine as an active ingredient,
( 2 ) テアニンの脂質利用促進作用により代謝促進作用が生じることを特徴 とする上記 (1 ) 記載の代謝促進組成物、  (2) The metabolism promoting composition according to the above (1), characterized in that metabolism promoting action is caused by the lipid utilization promoting action of theanine,
( 3 ) 代謝促進作用が、 持久力向上、 成長ホルモン分泌促進、 血糖値上昇、 脂肪燃焼、 有酸素運動時の疲労軽減、 嫌気性代謝閾値の上昇、 血中乳酸蓄積 の軽減、 抗疲労からなる群から選ばれるものであることを特徴とする上記 ( 1 ) 又は (2) 記載の代謝促進組成物、 (3) Metabolism-promoting action improves endurance, promotes growth hormone secretion, increases blood glucose levels, fat burning, reduces fatigue during aerobic exercise, increases anaerobic metabolic threshold, blood lactate accumulation The metabolism promoting composition according to the above (1) or (2), characterized in that it is selected from the group consisting of reducing fatigue and anti-fatigue,
(4) 体重 1 k g当たり 0. 5〜5mg/k gのテアニンを含有することを 特徴とする上記 (1 ) 〜 (3) のいずれか記載の代謝促進組成物、  (4) The metabolism promoting composition according to any one of (1) to (3) above, which contains 0.5 to 5 mg / kg theanine per 1 kg body weight,
(5) テアニンを 6〜600 Omg含有することを特徴とする上記 (1 ) 〜 (4) のいずれか記載の代謝促進組成物、  (5) The metabolism promoting composition according to any one of the above (1) to (4), comprising 6 to 600 Omg of theanine,
(6) 上記 (1 ) 〜 (5) のいずれか記載の代謝促進組成物を配合した飲食 物、  (6) A food or drink containing the metabolism promoting composition according to any one of (1) to (5) above,
(7) 上記 (1 ) 〜 (6) のいずれか記載の代謝促進組成物を経口摂取する ことを特徴とする代謝促進方法、  (7) A method for promoting metabolism, comprising orally ingesting the composition for promoting metabolism according to any one of (1) to (6) above,
(8) 代謝促進作用が、 脂質利用促進、 成長ホルモン分泌促進、 血糖値上昇 、 脂肪燃焼、 有酸素運動時の疲労軽減、 嫌気性代謝閾値の上昇、 血中乳酸蓄 積の軽減、 抗疲労からなる群から選ばれる 1又は 2以上の作用であることを 特徴とする上記 (7) 記載の代謝促進方法、  (8) Metabolism promoting action from lipid utilization promotion, growth hormone secretion promotion, blood sugar level increase, fat burning, fatigue reduction during aerobic exercise, anaerobic metabolic threshold increase, blood lactate accumulation reduction, anti-fatigue The method of promoting metabolism according to (7) above, wherein the method is one or more selected from the group consisting of:
(9) テアニンの投与量が、 1回の投与につき体重 1 k g当たり 0. 5〜5 mg/k gであることを特徴とする上記 (7) 又は (8) 記載の代謝促進方 法に関する。  (9) The method for promoting metabolism according to (7) or (8) above, wherein the dose of theanine is 0.5 to 5 mg / kg body weight per kilogram per administration.
発明の効果  The invention's effect
[0017] 本発明によれば、 安全性の高いエネルギー代謝促進組成物、 特に脂質利用促 進作用によりエネルギー代謝促進が生じる代謝促進組成物や、 該代謝促進組 成物を配合した飲食物や、 かかる代謝促進組成物や飲食物を経口摂取するこ とによる代謝促進方法を提供することができる。  [0017] According to the present invention, a highly safe energy metabolism promoting composition, particularly a metabolism promoting composition in which energy metabolism is promoted by a lipid utilization promoting action, a food and drink containing the metabolism promoting composition, It is possible to provide a method for promoting metabolism by orally ingesting such a metabolism promoting composition or food and drink.
発明を実施するための最良の形態  BEST MODE FOR CARRYING OUT THE INVENTION
[0018] 本欄では、 本発明の実施形態として、 代謝促進組成物ゃ該組成物を配合し た飲食物について説明する。 なお、 以下の説明において、 「Χ〜Υ」 (X, Υは任意の数字) と記載した場合、 特にことわらない限り 「X以上 Υ以下」 を意図し、 「Xよりも大きく Υよりも小さいことが好ましい」 旨の意図も包 含する。 [0019] 本発明の代謝促進組成物は、 テアニンを有効成分として配合させることに より調製することができる。 これらの組成物は、 食品や飲料に配合すること ができる。 なお、 かかる代謝促進組成物やこれを配合した飲食品は、 テア二 ンを配合することにより調製することができるが、 テアニンを含有する組成 物、 植物抽出物、 飲食品やその他テアニン含有物を配合することにより調製 することもできる。 [0018] In this section, as an embodiment of the present invention, a metabolism promoting composition and a food and drink containing the composition will be described. In addition, in the following explanation, when “Χ ~ Υ” (X, 数字 is any number), unless otherwise stated, it is intended to be “X or more and」 or less ”,“ greater than X and smaller than Υ The intention of “preferably” is also included. [0019] The metabolism promoting composition of the present invention can be prepared by incorporating theanine as an active ingredient. These compositions can be incorporated into foods and beverages. Such metabolism promoting compositions and foods and drinks containing the same can be prepared by adding theanine. However, compositions containing theanine, plant extracts, foods and drinks and other theanine-containing substances It can also be prepared by blending.
[0020] テアニンは、 緑茶等に含まれるグルタミン酸の誘導体であり、 本発明の有 効成分として、 例えば L—グルタミン酸 ェチルアミ ド (L—テアニン ) 、 L—グルタミン酸 _ _メチルアミ ド、 D—グルタミン酸 _ _ェチル アミ ド (D—テアニン ) 、 D—グルタミン酸 _ _メチルアミ ド等の L—ま たは D—グルタミン酸一 —アルキルアミ ド、 L—または D—グルタミン酸 _ —アルキルアミ ドを基本構造に含む誘導体 (例えば L_または D—グル タミン酸— : Γ_アルキルアミ ドの配糖体など) からなる群から選ばれた 1種 類の化合物又は 2種類以上の化合物からなる混合物を用いることができる。 中でも、 L_テアニンは、 天然物から取得可能であるばかりか、 食品添加物 として認められており、 入手の容易さ及び安全性などからも特に好ましい。  [0020] Theanine is a derivative of glutamic acid contained in green tea and the like. As an active ingredient of the present invention, for example, L-glutamic acid ethylamide (L-theanine), L-glutamic acid __ methyl amide, D-glutamic acid __ Derivatives containing L- or D-glutamic acid mono-alkyl amides, L- or D-glutamic acid _ -alkyl amides in the basic structure (eg L-amino acid (D-theanine), D-glutamic acid _ _methyl amide, etc.) _ Or D-glutamic acid: a glycoside of Γ_alkyl amide, etc.) and a mixture of one or more compounds selected from the group consisting of two or more compounds can be used. Of these, L-theanine is not only obtainable from natural products, but is also recognized as a food additive, and is particularly preferred from the standpoint of availability and safety.
[0021] テアニンは、 既に公知となっている各種方法によって製造することが可能で ある。 例えば、 植物または微生物などの培養法により生合成することも、 茶 葉から抽出することも、 発酵或いは化学合成することもできる。 具体的には 、 特開平 05— 068578 (段落 [ 0006]-[0021 ]) 、 特開平 5 - 328986 (段落 [ 0008]-[0027]) 、 特開平 09— 263573 (段落 [ 0009]-[0029]) 、 特開平 1 1—225789 (段落 [ 000 7]-[0021 ]) 、 特開 2000— 26383 (段落 [ 0006 ] _ [ 002 0 ] ) 、 特開 2001 _ 278848 (段落 [ 001 1 ]-[0021 ]) 、 特開 2003-267867 (段落 [ 0005]-[001 7]) 、 特開 2004— 01 0545 (段落 [ 0006]-[0036]) 、 特開 2006— 0831 5 5 (段落 [0009]_[0021 ]) 等に記載された製造方法によって得るこ とができる。 ただし、 これらの製造方法に限定されるわけではない。 また、 得られたテアニンはそのまま使用しても精製して使用してもよく、 両者を混 合して使用することもできる。 [0021] Theanine can be produced by various known methods. For example, it can be biosynthesized by a culture method of plants or microorganisms, extracted from tea leaves, fermented or chemically synthesized. Specifically, JP-A-05-068578 (paragraphs [0006]-[0021]), JP-A-5-328986 (paragraphs [0008]-[0027]), JP-A-09-263573 (paragraphs [0009]-[0029]). ]), JP-A-11-225789 (paragraph [000 7]-[0021]), JP-A 2000-26383 (paragraph [0006] _ [002 0]), JP-A-2001_278848 (paragraph [0011]- [0021]), JP 2003-267867 (paragraphs [0005]-[001 7]), JP 2004-01 0545 (paragraphs [0006]-[0036]), JP 2006-0831 5 5 (paragraph [0009] ] _ [0021]) and the like. However, it is not necessarily limited to these manufacturing methods. Also, The obtained theanine may be used as it is, or may be used after purification, or a mixture of both.
[0022] 本発明において、 テアニンは、 本発明の代謝促進組成物の有効成分として単 独で用いることもできるが、 他の成分と混合して用いることもできる。 また 、 テアニンは、 精製品、 粗精製品、 茶抽出エキス等の形状、 精製水又は生理 食塩水などに溶解物として使用することもできる。  [0022] In the present invention, theanine can be used alone as an active ingredient of the metabolism-promoting composition of the present invention, but can also be used by mixing with other components. Theanine can also be used as a lysate in purified products, crude products, tea extract extracts, purified water or physiological saline.
[0023] 本発明において代謝とは、 生体内の化学反応を一般的に意味するものであ り、 体外から取り入れた物質から他の物質を合成したり、 エネルギーを得た りすることをいう。 本発明において代謝促進 (活動代謝) とは、 エネルギー 代謝を促進することを指すものであって薬物代謝を含むものではない。 エネ ルギ一代謝には、 身体を動かすことによりエネルギーを消費するもの (活動 代謝) と、 身体を動かさずに何もしないでも消費されるエネルギーであって 生命維持に必要最小限のもの (基礎代謝) とがある。 本発明において代謝促 進とは、 有効成分であるテアニンの脂質の利用を促進させることにより、 も つて代謝促進が促進させることをいう。  [0023] Metabolism in the present invention generally means a chemical reaction in a living body, and refers to synthesizing another substance or obtaining energy from a substance taken from outside the body. In the present invention, metabolism promotion (activity metabolism) refers to promotion of energy metabolism and does not include drug metabolism. There are two types of energy metabolism: energy consumed by moving the body (activity metabolism) and energy consumed without moving the body and doing nothing (basal metabolism). There is. In the present invention, the promotion of metabolism means that the promotion of metabolism is promoted by promoting the utilization of lipids of theanine which is an active ingredient.
[0024] 本発明において 「持久力向上」 とは、 持久力を必要とする運動や筋肉労作 を繰り返し行う必要のある労働等を始めとする広義の運動に対して持久力を 向上、 疲労を抑制する作用を有することをいう。 本発明における代謝促進組 成物は、 テアニンを有効成分として含有し、 かかる作用を有する組成物をい ラ。  [0024] In the present invention, "improve endurance" means improving endurance and suppressing fatigue in a broad sense of exercise, such as work that requires endurance and labor that requires repeated muscle work. It has the effect | action which carries out. The metabolism promoting composition in the present invention is a composition containing theanine as an active ingredient and having such an action.
[0025] 本発明において 「有酸素運動時の疲労軽減」 とは、 マラソン、 水泳、 エア 口ビクス等の持久力を必要とする運動、 さらには日常生活における労作等、 筋肉における酸素消費と心肺系による酸素の供給が平衡状態にある、 いわゆ る有酸素運動を行うときに生じる身体的疲労を軽減する作用を有することを いう。 疲労には身体的疲労と精神的疲労とに一般的に大別されるが、 本発明 の組成物は有酸素運動により生じる身体的疲労を軽減するものであって、 精 神的疲労のみに直接作用するものではない。 しかし、 身体的疲労と精神的疲 労との両方の状態にある場合に、 本発明の代謝促進組成物を投与することに より身体的疲労を軽減することができるのはいうまでもない。 [0025] In the present invention, "reducing fatigue during aerobic exercise" means exercise that requires endurance, such as marathon, swimming, and air mouth bicus, and further work in daily life, such as oxygen consumption in the muscles and the cardiopulmonary system. This means that the oxygen supply by the body is in an equilibrium state and has the action of reducing physical fatigue that occurs when performing so-called aerobic exercise. Fatigue is generally broadly divided into physical fatigue and mental fatigue. The composition of the present invention reduces physical fatigue caused by aerobic exercise, and is directly applied only to spiritual fatigue. It does not work. However, in the case of both physical fatigue and mental fatigue, it is necessary to administer the metabolism promoting composition of the present invention. Needless to say, physical fatigue can be reduced.
[0026] 本発明において嫌気性代謝閾値上昇とは、 体内で乳酸が血中に蓄積し始め る時点の酸素摂取量の値を上昇させることをいう。 乳酸は骨格筋に対してェ ネルギ一源として利用されるため疲労時の重要な回復因子の一つとなる。 さ らに脳、 心臓においてもその重要性が指摘されている ( 『別冊■医学の歩み :疲労の化学』 第 1 4頁、 2 0 0 5 ) 。 しかし、 筋肉中での乳酸の過度の蓄 積は、 筋の活動を低下させることによりパフォーマンスの低下の原因となる 。 このため筋肉中の乳酸の蓄積を抑制することは、 疲労を予防する上で重要 である。  In the present invention, an increase in the anaerobic metabolic threshold means an increase in the value of oxygen intake at the time when lactic acid begins to accumulate in the blood in the body. Lactic acid is used as a source of energy for skeletal muscle and is therefore an important recovery factor during fatigue. In addition, its importance has been pointed out in the brain and heart ("Separate volume ■ History of medicine: Fatigue chemistry", p. 14, p. 205). However, excessive accumulation of lactic acid in the muscle causes performance degradation by reducing muscle activity. Therefore, suppressing the accumulation of lactic acid in the muscle is important in preventing fatigue.
[0027] 嫌気性閾値代謝値 (anaerob i c thresho l d, A T値) とは、 「乳酸が血中に蓄 積し始める時点の酸素摂取量の値」 と定義されている ( 『運動負荷試験入門 』 第1 4 8頁、 2001 ) 。 嫌気性閾値代謝値は、 もともと Wassermanにより提唱 されたものであり、 現在は呼気ガス分析を併用する運動負荷試験において標 準的に用いられるものである。  [0027] Anaerobic threshold metabolism (anaerobic threshold, AT value) is defined as “the value of oxygen intake at the time when lactate begins to accumulate in the blood” (“Introduction to Exercise Testing”) 1 48, 2001). The anaerobic threshold metabolic value was originally proposed by Wasserman, and is currently used as a standard in exercise testing combined with breath gas analysis.
[0028] 運動強度を徐々に増加させる漸増負荷運動において、 換気量 (肺呼吸量) や 血中乳酸濃度は初期段階において緩やかに増加していく力 ある特定段階で 有酸素運動から無酸素運動に変わることから、 換気量 (肺呼吸量) や血中乳 酸濃度は急激に増加する。 この変曲点、 すなわち無酸素運動と有酸素運動の 境界の運動強度は、 無酸素性代謝閾値又は嫌気性代謝閾値と呼ばれている。 すなわち嫌気性閾値代謝値とは、 いかに高強度の運動ができるかを数値で示 すものであって有酸素性持久力の指標とされている。 本発明における代謝促 進組成物は、 テアニンを有効成分として含有し、 かかる作用を有する組成物 をいう。  [0028] In increasing load exercise that gradually increases exercise intensity, ventilation (pulmonary respiration) and blood lactate concentration gradually increase at the initial stage. From aerobic exercise to anaerobic exercise at a specific stage. Because it changes, ventilation (pulmonary respiration) and blood lactate concentration increase rapidly. This inflection point, the exercise intensity at the boundary between anaerobic and aerobic exercise, is called the anaerobic metabolic threshold or anaerobic metabolic threshold. In other words, the anaerobic threshold metabolic value is a numerical value indicating how high intensity exercise is possible, and is an index of aerobic endurance. The metabolism promoting composition in the present invention refers to a composition containing theanine as an active ingredient and having such an action.
[0029] 本発明において血中乳酸蓄積軽減とは、 血中の乳酸蓄積を抑制する作用を指 すものであるが、 かかる血中乳酸蓄積軽減には血中の乳酸を減少させる作用 も含まれる。 上述のとおり、 乳酸は筋肉等の疲労回復因子とされており、 効 率的に乳酸が利用されることは疲労回復の点からも望ましい。 かかる乳酸蓄 積が抑制されれば、 筋の活動低下を抑制し、 より強度が高い運動を行うこと ができる。 [0029] In the present invention, blood lactate accumulation reduction refers to an action of suppressing blood lactate accumulation, and such blood lactate accumulation reduction also includes an action of reducing blood lactate. . As mentioned above, lactic acid is considered to be a factor for fatigue recovery of muscles and the like, and the efficient use of lactic acid is desirable from the viewpoint of recovery from fatigue. If this accumulation of lactic acid is suppressed, it is possible to suppress muscle activity decline and exercise more intensely. Can do.
[0030] 本発明において成長ホルモンとは、 視床下部から分泌される成長ホルモン放 出ホルモン (G H R H ) の作用を受けて、 下垂体前葉の G H分泌細胞から分 泌されるホルモンをいう。 成長ホルモンは、 生体の成長に関与しており、 タ ンパク質合成、 窒素バランス、 炭水化物代謝、 脂肪代謝、 カルシウムのホメ ォスタシスなど体内の代謝メ力ニズム全般をコント口一ルするものである。 炭水化物代謝とは血糖値の調節を指す。 血糖値が過剰上昇すると、 高血糖や 糖尿病等の疾患の原因となり好ましくない。 しかし、 血糖値が低下すると精 神的焦燥感 (イライラ感等) を引き起こし、 さらに過剰に低下した場合には 大量の冷や汗、 動悸、 手のふるえ等身体上の以上を引き起こし、 ひいては死 に至ることもある。 また血糖値の低下は身体的活動が出来なくなり疲労状態 となる。 よって成長ホルモンを介して適度な血糖値を維持することが必要で ある。 本発明において代謝促進祖組成物とは、 生体内でかかる成長ホルモン の分泌を促進する物質をいう。  [0030] In the present invention, growth hormone refers to a hormone secreted from GH-secreting cells in the anterior pituitary gland under the action of growth hormone-releasing hormone (GHRH) secreted from the hypothalamus. Growth hormone is involved in the growth of the body and controls all metabolic mechanisms in the body, such as protein synthesis, nitrogen balance, carbohydrate metabolism, fat metabolism, and calcium homeostasis. Carbohydrate metabolism refers to the regulation of blood sugar levels. An excessive increase in blood glucose level is not preferable because it may cause diseases such as hyperglycemia and diabetes. However, when the blood glucose level falls, it causes a feeling of spiritual frustration (feeling irritated, etc.), and when it falls excessively, it causes a lot of cold, sweat, palpitation, hand tremors, etc., resulting in death. There is also. In addition, a decrease in blood glucose level results in fatigue due to inability to perform physical activities. Therefore, it is necessary to maintain an appropriate blood glucose level through growth hormone. In the present invention, the metabolism-promoting progenitor composition refers to a substance that promotes the secretion of growth hormone in vivo.
[0031 ] 本発明において血糖値とは、 血液内のブドウ糖 (g l ucose)の濃度をいう。 血糖 値は、 通常の状態では血糖を下げるインスリンと、 血糖を上げるグルカゴン の作用とによって非常に狭い範囲の正常値に調節されている。 食事後血糖値 が上昇すると、 グルコースは G L U T 2又は G L U T 1 トランスポ一タ一を 通って塍; S細胞に流入する。 グルコキナーゼの作用によりグルコースがグル コース 6リン酸になると、 細胞内にカルシウムイオンの流入が起こり、 イン スリンが放出される。 健常なヒ卜の場合空腹時血糖値は概ね 8 0 _ 1 O O m g / d I程度であり、 食後は若干高い値を示すといわれている。 血糖値が過 剰上昇すると、 高血糖や糖尿病等の疾患の原因となり好ましくない。 しかし 、 血糖値が過剰低下すると低血糖状態となり精神的焦燥感 (イライラ感等) を引き起こし、 悪化すると大量の冷や汗、 動悸、 手のふるえ等身体上の異常 を引き起こし、 ひいては死に至ることもある。 また血糖値の低下は身体的活 動が出来なくなり疲労状態となる。 よって適度な血糖値を維持することが必 要である。 本発明において代謝促進祖組成物とは、 生体内でかかる血糖値上 昇を促進する物質をいう。 [0031] In the present invention, the blood glucose level refers to the concentration of glucose in the blood. The blood glucose level is adjusted to a normal value within a very narrow range by the action of insulin that lowers blood sugar and the action of glucagon that raises blood sugar under normal conditions. When blood glucose levels rise after a meal, glucose passes through the GLUT 2 or GLUT 1 transporter; it flows into S cells. When glucose is converted to glucose 6-phosphate by the action of glucokinase, calcium ions flow into the cell and insulin is released. In healthy chicks, the fasting blood glucose level is approximately 80 _ 1 OO mg / d I, which is said to be slightly higher after meals. An excessive rise in blood glucose level is not preferable because it causes diseases such as hyperglycemia and diabetes. However, if the blood glucose level is excessively lowered, it becomes hypoglycemic and causes a feeling of mental agitation (irritability, etc.). In addition, a decrease in blood glucose level results in fatigue and a lack of physical activity. Therefore, it is necessary to maintain an appropriate blood sugar level. In the present invention, the metabolic promoter composition refers to the blood glucose level in vivo. A substance that promotes ascent.
[0032] 本発明において脂肪燃焼とは、 体内に貯えられた脂肪を燃やす体脂肪燃焼作 用を主として指すものであるが、 脂肪が体内吸収されることを阻害すること による脂肪蓄積抑制作用も含むものである。 本発明の代謝促進組成物を摂取 することにより、 テアニンが生体内における脂質の利用を促進し、 もって体 脂肪燃焼作用や脂肪蓄積抑制作用が得られる。  [0032] In the present invention, fat burning mainly refers to a body fat burning action that burns fat stored in the body, but also includes an action of suppressing fat accumulation by inhibiting fat absorption in the body. It is a waste. By ingesting the metabolism-promoting composition of the present invention, theanine promotes the utilization of lipids in the living body, thereby obtaining body fat burning action and fat accumulation inhibiting action.
[0033] 本発明において抗疲労とは、 身体的疲労の発生、 身体疲労の回復及び持久力 の維持■向上を指すものである。 本発明の代謝促進組成物を摂取することに より、 テアニンが生体内の脂質や糖質の利用を促進し、 もって抗疲労作用、 疲労回復作用、 持久力維持作用、 持久力向上作用、 滋養強壮作用が得られる  [0033] In the present invention, anti-fatigue refers to occurrence of physical fatigue, recovery of physical fatigue, and maintenance / improvement of endurance. By ingesting the metabolism promoting composition of the present invention, theanine promotes utilization of lipids and carbohydrates in the living body, and thus has anti-fatigue action, fatigue recovery action, endurance maintenance action, endurance improvement action, nourishing tonic The effect is obtained
[0034] 本発明の代謝促進組成物は、 医薬品および医薬部外品として提供することが できる。 [0034] The metabolism promoting composition of the present invention can be provided as a pharmaceutical and a quasi-drug.
[0035] その形態としては、 凍結乾燥或いは噴霧乾燥等により乾燥させて乾燥粉末と して提供することも、 液剤、 錠剤、 散剤、 顆粒、 糖衣錠、 カプセル、 懸濁液 、 乳剤、 アンプル剤、 注射剤、 その他任意の形態に調製して提供することが できる。 医薬品として提供する場合、 例えば、 有効成分をそのまま精製水又 は生理食塩水などに溶解して調製することも可能である。 医薬部外品として 提供する場合、 容器詰めドリンク飲料等の飲用形態、 或いはタブレット、 力 プセル、 顆粒等の形態とし、 できるだけ摂取し易い形態として提供するのが 好ましい。  [0035] As its form, it may be dried by freeze-drying or spray-drying, etc. and provided as a dry powder, or it may be a liquid, tablet, powder, granule, dragee, capsule, suspension, emulsion, ampoule, injection It can be prepared and provided in any form. When provided as a pharmaceutical product, for example, the active ingredient can be prepared by dissolving it in purified water or physiological saline as it is. When it is provided as a quasi-drug, it is preferably provided in a form that is easy to ingest as much as possible, such as a drinking form such as a container-packed drink, or a form such as a tablet, force capsule, or granule.
[0036] また、 本発明の代謝促進組成物は飲食物素材に添加することもできる。 なお 、 本明細書中において飲食物とは、 飲料や食品を意図している。  [0036] The metabolism promoting composition of the present invention can also be added to food and drink materials. In the present specification, food and drink are intended for beverages and foods.
[0037] このような飲食物は、 健康食品■健康飲料■特定保健用食品■機能性食品と して提供することができる。 その場合、 それぞれの飲食物を製造するのに通 常配合する食品素材に本発明の代謝促進組成物を添加することにより調製で きる。 また、 特定保健用食品等の認定を受けた場合に、 これらの飲食物は、 テアニンを含有し、 代謝促進のために用いられるものである旨の表示を付し た食品又は飲料として販売することもできる。 [0037] Such foods and drinks can be provided as health foods, health drinks, foods for specified health use, functional foods. In that case, it can be prepared by adding the metabolism-promoting composition of the present invention to food materials that are usually blended to produce each food and drink. In addition, when approved as food for specified health use, etc., these foods and drinks shall contain a label indicating that they contain theanine and are used to promote metabolism. It can also be sold as a fresh food or beverage.
[0038] 例えば、 本発明の有効成分を、 各種食品素材 (果実やゼリーなども含む) 、 乳成分、 炭酸、 賦形剤 (造粒剤含む) 、 希釈剤、 或いは更に甘味剤、 フレー バー、 小麦粉、 でんぷん、 糖、 油脂類等の各種タンパク質、 糖質原料ゃビタ ミン、 ミネラル、 その他の生理活性成分、 ホルモン、 栄養成分などから選ば れた一種又は二種以上に加えて、 スポーツ飲料、 果実飲料、 茶飲料、 野菜ジ ユース、 乳性飲料、 アルコール飲料、 ゼリー飲料、 炭酸飲料などの各種飲料 、 ゼリー、 チューインガム、 チョコレート、 アイスクリーム、 キャンディ、 ビスケットなどの菓子類、 スナック、 パン、 ケーキなどの澱粉系加工食品、 魚肉練り製品、 畜肉製品、 豆腐、 チーズなどのタンパク質系加工食品、 味噌 やしようゆ、 ドレッシングなどの調味料、 その他、 サプリメント、 飼葉、 ぺ ットフ一ドなど様々な飲食物の形態として提供することができる。  [0038] For example, the active ingredient of the present invention may be a variety of food materials (including fruits and jelly), milk ingredients, carbonic acid, excipients (including granulating agents), diluents, or even sweeteners, flavors, In addition to one or more selected from various proteins such as wheat flour, starch, sugar, fats and oils, carbohydrate raw materials, vitamins, minerals, other physiologically active ingredients, hormones, nutritional ingredients, sports drinks, fruits Beverages, tea beverages, vegetable drinks, milk beverages, alcoholic beverages, jelly beverages, carbonated beverages and other beverages, jelly, chewing gum, chocolate, ice cream, candy, biscuits and other sweets, snacks, bread, cakes, etc. Starch-based processed foods, fish paste products, livestock meat products, tofu, cheese and other protein-based processed foods, miso soy sauce, dore Seasonings such as single, other supplements, fodder, can be provided in the form of various food such as Bae Ttofu one de.
[0039] 上記組成物および飲食物におけるテアニン量は、 本発明が目的とする効果 を損なわない限り特に限定するものではないが、 例えば投与対象の体重 1 k g当たり 0. 5m g〜5mgのテアニンを投与するのが好ましく、 中でも投 与対象の体重 1 k g当たり 0. 5m g〜2mgのテアニンを投与するのがさ らに好ましい。 例えば本発明の組成物を成人に投与することを想定し、 体重 を 40 k g〜 1 O O k gとした場合、 2 Om g〜50 Om gのテアニンを投 与することが好ましく、 20mg〜20 Om gのテアニンを投与することが さらに好ましい。 言い換えれば、 そのようなテアニン量を摂取し得るように 組成物および飲食物中のテアニン量を適宜調整するのが好ましい。  [0039] The amount of theanine in the composition and food and drink is not particularly limited as long as it does not impair the intended effect of the present invention. For example, 0.5 mg to 5 mg of theanine per 1 kg of the body weight of the administration subject. Preferably, 0.5 mg to 2 mg of theanine is administered per kg of the subject's body weight. For example, assuming that the composition of the present invention is administered to an adult and the body weight is 40 kg to 1 OO kg, it is preferable to administer 2 Omg to 50 Omg of theanine, and 20 mg to 20 Omg. More preferably, theanine is administered. In other words, it is preferable to appropriately adjust the amount of theanine in the composition and food and drink so that the amount of theanine can be ingested.
[0040] 例えば、 体重 60 k gのヒトが摂取することを目安とすると、 3mg〜3 00 Omgのテアニン含有量に調整するのが好ましく、 中でも 3mg〜 1 2 Omgのテアニン含有量に調整するのがさらに好ましい。  [0040] For example, when it is taken as a guide for a person weighing 60 kg, it is preferable to adjust the theanine content to 3 mg to 300 Omg, and in particular, to adjust the theanine content to 3 mg to 12 Omg. Further preferred.
実施例  Example
[0041] 以下、 本発明を実施例によってさらに具体的に説明するが、 本発明は下記 実施例に限定されるものではない。  [0041] Hereinafter, the present invention will be described more specifically with reference to examples. However, the present invention is not limited to the following examples.
[0042] (実施例 1 ) : テアニンの脂質利用促進作用 実験には雄マウス C D F 1 ( 1 0週齢、 2 0匹) を用いた。 テアニンは、 L—テアニンを純水に溶解してテアニン溶液を調製して、 これを試料とした [0042] (Example 1): Theanine promotes lipid utilization In the experiment, male mouse CDF 1 (10 weeks old, 20 animals) was used. Theanine was prepared by dissolving L-theanine in pure water to prepare a theanine solution.
[0043] テアニン投与群 (1 0匹) は、 回転かごにて 1 8 0分間自発運動させてマ ウスに運動負荷をかけた後、 5分間休息させてから、 テアニン 0 . 5 m g / k gを腹腔内投与し、 投与後 3 0分間休息させ、 その後再度 1 8 0分間回転 かごにて自発運動させた。 [0043] In the theanine administration group (10 animals), the mouse was exercised for 180 minutes in a rotating basket, exercised on the mouse, rested for 5 minutes, and then 0.5 mg / kg of theanine was applied. After intraperitoneal administration, the patient was rested for 30 minutes after administration, and then spontaneously exercised again in a rotating basket for 180 minutes.
[0044] 他方、 コントロール投与群 (1 0匹) は、 回転かごにて 1 8 0分間自発運 動させてマウスに運動負荷をかけた後、 5分間休息させてから腹腔内投与し 、 投与後 3 0分間休息させ、 その後再度 1 8 0分間回転かごにて自発運動さ せた。  [0044] On the other hand, in the control administration group (10 animals), the mice were spontaneously operated in a rotating basket for 180 minutes and subjected to exercise load on the mice, then rested for 5 minutes and then administered intraperitoneally. He rested for 30 minutes, and then moved again for 80 minutes in a rotating basket.
[0045] それぞれの投与群について、 1回目の運動量 (回転数) と 2回目との運動 量 (回転数) を測定する共に、 各運動の直後に心採血を行い、 血中遊離脂肪 酸濃度を測定した。 相対運動量について、 コントロール投与群 (DW) とテ ァニン投与群 (thean i ne) とを比較した結果を図 1に、 血中脂肪酸濃度につ いて、 コントロール投与群 (DW) とテアニン投与群 (thean i ne) とを比較 した結果を図 2に示す。  [0045] For each administration group, the first exercise amount (number of rotations) and the second amount of exercise (number of rotations) were measured, and heart blood was collected immediately after each exercise to determine the free fatty acid concentration in the blood. It was measured. Figure 1 shows a comparison of the relative momentum between the control administration group (DW) and the theanine administration group (theanine). Regarding the blood fatty acid concentration, the control administration group (DW) and the theanine administration group (theanine) Fig. 2 shows the result of comparison with i ne).
[0046] (実験手順)  [0046] (Experimental procedure)
1回目の運動 (回転運動 1 8 0分間) →腹腔内投与→休憩 3 0分間→ 2回 目の運動 (回転運動 1 8 0分間)  1st exercise (rotary motion 1800 minutes) → intraperitoneal administration → break 30 minutes → 2nd exercise (rotary motion 1800 minutes)
[0047] (結果■考察)  [0047] (Result ■ Consideration)
コントロール投与群では 2回目の運動量は 2 0 %以下に抑えられたが、 テ ァニン投与群では 5 0 %以上保持していた。 一方、 血中の遊離脂肪酸は、 テ ァニン投与群の方が明らかに高く、 脂質の利用が促進されていることが確認 できた。 このことから、 テアニンを投与することにより、 中性脂肪の分解を 促進して血液中の遊離脂肪酸量を増やし、 エネルギー源として細胞に供給す る血中遊離脂肪酸量を増加させることができ、 このように脂質利用を促進で きることが判明した。 [0048] (実施例 2) : テアニンの身体疲労軽減作用■持久力向上作用 実験には雄マウス CD F 1 (6週齢、 4匹) を用いた。 テアニンは、 L— テアニンを純水に溶解してテアニン濃度 0. 05mg/m Iのテアニン溶液 を調製して、 これを試料とした。 In the control group, the amount of exercise for the second time was suppressed to 20% or less, but in the theanine group, it was maintained at 50% or more. On the other hand, the free fatty acids in the blood were clearly higher in the theanine administration group, confirming that lipid utilization was promoted. Therefore, administration of theanine can promote the breakdown of triglycerides and increase the amount of free fatty acids in the blood, increasing the amount of free fatty acids in the blood supplied to cells as an energy source. Thus, it was found that lipid utilization can be promoted. (Example 2): Theanine's action to reduce body fatigue ■ Endurance improving action Male mice CD F 1 (6 weeks old, 4 animals) were used in the experiment. For theanine, L-theanine was dissolved in pure water to prepare a theanine solution with a theanine concentration of 0.05 mg / m I, and this was used as a sample.
[0049] テアニン投与群 (4匹) は、 回転かごにて 1 80分間自発運動させてマウ スに運動負荷をかけた後、 5分間休息させてから、 テアニン 0. 5mg/k gを経口投与し、 投与後 30分間休息させ、 その後再度 1 80分間回転かご にて自発運動させた。 [0049] In the theanine administration group (4 animals), after exercising for 80 minutes in a rotating basket and applying exercise to the mouse, resting for 5 minutes and then orally administering theanine 0.5 mg / kg. After the administration, the patient was rested for 30 minutes, and then spontaneously exercised again in a rotating basket for 180 minutes.
[0050] 他方、 コントロール投与群 (4匹) は、 回転かごにて 1 80分間自発運動 させてマウスに運動負荷をかけた後、 5分間休息させてから、 純水 1 Om I /k gを経口投与し、 投与後 30分間休息させ、 その後再度 1 80分間回転 かごにて自発運動させた。  [0050] On the other hand, in the control administration group (4 animals), the mice were exercised for 180 minutes in a rotating basket and subjected to exercise load, and then rested for 5 minutes, and then pure water 1 Om I / kg was orally administered. After administration, the patient was allowed to rest for 30 minutes, and then again exercised again for 180 minutes in a rotating basket.
[0051] それぞれの投与群について、 1回目の運動時の回転かごの回転数と 2回目 の回転数を測定し、 回転数の減少数 (回) を求めた。 コントロール投与群 ( 水投与群) とテアニン投与群とを比較した結果を図 3に示した。  [0051] For each administration group, the number of rotations of the rotating cage during the first exercise and the number of rotations of the second time were measured, and the number of rotation reductions (times) was determined. The results of comparing the control administration group (water administration group) and the theanine administration group are shown in FIG.
[0052] (実験手順)  [0052] (Experimental procedure)
1回目の運動 (回転運動 1 80分間) →経口投与→休憩 30分間→ 2回目 の運動 (回転運動 1 80分間)  1st exercise (rotation 1 80 minutes) → Oral administration → break 30 minutes → 2nd exercise (rotation 1 80 minutes)
[0053] (結果)  [0053] (Result)
水投与群では 700回以上の回転数減少が認められたが、 テアニン投与群 では 2回目の回転数がむしろ増加した。 このことから、 テアニンは、 身体疲 労時における持久力を向上させ、 身体疲労軽減効果を発揮することが明らか となった。  In the water-administered group, a decrease in rotation speed of 700 times or more was observed, but in the theanine-administered group, the second rotation speed was rather increased. From this, it was clarified that theanine improves endurance at the time of physical fatigue and exerts an effect of reducing physical fatigue.
[0054] (実施例 3) : テアニンの有効濃度の確認  [0054] (Example 3): Confirmation of effective concentration of theanine
実験には雄マウス CD F 1 (7週齢、 7匹) を用いた。 テアニンは、 L— テアニンを純水に溶解してテアニン濃度 0. 02mg/m l、 0. 05mg I、 0. 1 5mg/m Iのテアニン溶液を調製し、 試料とした。  Male mice CD F 1 (7 weeks old, 7 mice) were used in the experiment. For theanine, L-theanine was dissolved in pure water to prepare theanine solutions with theanine concentrations of 0.02 mg / ml, 0.05 mg I, 0.15 mg / ml and used as samples.
[0055] 1週間の予備飼育後、 選抜試験を行った。 この選抜試験では、 1 80分間 回 [0055] After one week of preliminary breeding, a selection test was conducted. In this selection test, 1 80 minutes Times
転かごにて自発運動をさせて運動負荷をかけ、 5分間休息させてから水を経 口投与した。 投与後 30分間休息させ、 その後再度 1 80分間回転かごにて 自発運動させた。 1回目の運動時の回転かごの回転数と 2回目の回転数を測 定した。  A self-exercising exercise was performed with a rolling basket, and exercise load was applied. After resting for 5 minutes, water was administered orally. After the administration, the patient was rested for 30 minutes, and then spontaneously exercised again in a rotating basket for 180 minutes. The number of rotations of the rotating cage during the first exercise and the number of rotations of the second time were measured.
選抜基準としては、 2回目の運動量 (回転数) から 1回目の運動量 (回転 数) を引いた差分が— 300回以上 2000回以下の個体を選抜した。  As selection criteria, individuals with a difference of –300 times or more and 2000 times or less from the second momentum (number of revolutions) minus the first momentum (number of revolutions) were selected.
[0056] 本試験では、 選抜された個体 (28匹) を対象として、 水の代わりにテア ニンを経口投与する以外は、 選抜試験と同一のプロ トコルにて行った。 但し[0056] In this study, selected individuals (28 animals) were subjected to the same protocol as the selection test, except that theanine was orally administered instead of water. However,
、 コントロール群には水を投与した。 テアニンの投与量は、 公比約 3で 0.The control group received water. Theanine dose is about 3 at a common ratio of 0.
2mg/k g、 0. 5mg/k g、 1. 5mg/k gとし 。 2 mg / kg, 0.5 mg / kg, 1.5 mg / kg.
[0057] 2回目の運動量 (回転数) から 1回目の運動量 (回転数) を引いた差分を[0057] The difference obtained by subtracting the first momentum (number of revolutions) from the second momentum (number of revolutions)
、 回転数の減少数 (回) として、 各投与群毎に回転数の減少数を示したグラ フを図 4に示した。 Fig. 4 shows a graph showing the number of rotation reductions for each administration group as the number of rotation reductions (times).
[0058] (実験手順) [0058] (Experimental procedure)
1回目の運動 (回転運動 1 80分間) →経口投与→休憩 30分間→ 2回目 の運動 (回転運動 1 80分間)  1st exercise (rotation 1 80 minutes) → Oral administration → break 30 minutes → 2nd exercise (rotation 1 80 minutes)
[0059] (結果) [0059] (Result)
全てのテアニン投与群で回転数減少抑制効果が認められた。 このことから 、 少なくとも 0. 2 m g/ k g以上のテアニンを投与することで、 身体疲労 時における持久力を向上させ、 身体疲労を軽減させることが明らかとなった  In all theanine-administered groups, an effect of suppressing the decrease in rotation speed was observed. From this, by administering at least 0.2 mg / kg or more of theanine, it became clear that the endurance at the time of physical fatigue was improved and the physical fatigue was reduced.
[0060] (実施例 4) : テアニンの持久力向上作用 [0060] (Example 4): Endurance enhancing action of theanine
テアニンの持久力向上作用を強制遊泳試験により調べた。 実験には、 雄マウ ス CD F 1 (6週齢、 8匹) を用いた。 テアニンは、 L—テアニンを純水に 溶解してテアニン濃度 0. 02mg/m l、 0. 05mg/m l、 0. 1 5 mg/m Iのテアニン溶液を調製し、 試料とした。  The endurance improvement effect of theanine was investigated by forced swimming test. Male mice CDF 1 (6 weeks old, 8 animals) were used in the experiment. For theanine, L-theanine was dissolved in pure water to prepare theanine solutions having theanine concentrations of 0.02 mg / ml, 0.05 mg / ml, and 0.15 mg / ml, and used as samples.
[0061] 2日間のトレーニング後、 1 日おきに 3回選抜試験を行った。 選抜試験で は、 流水槽 (流量 8 L/m i n、 水温 34°C、 平均流速を 23〜24 cm/ s e cに設定) に入れて遊泳させ、 限界遊泳時間を測定した。 このとき、 遊 泳しているマウスが常に流水槽内に 6匹ずついるようにダミーマウスを用い て試験した。 選抜基準は、 遊泳時間の S. D. が 1 4分以内であることとし た。 また、 群分けには連続無作為化法を用いた。 [0061] After two days of training, selection tests were conducted three times every other day. In the selection test Was placed in a flowing water tank (flow rate 8 L / min, water temperature 34 ° C, average flow rate set to 23-24 cm / sec) and allowed to swim, and the limit swimming time was measured. At this time, dummy mice were used for the test so that there were always 6 mice swimming in the water tank. The selection criteria were that the swimming time SD was within 14 minutes. In addition, a continuous randomization method was used for grouping.
[0062] 本試験では選抜された個体 (各群 8匹) を対象として、 各マウスを一夜 ( 約 1 5時間) 絶食させた後、 テアニン又は水を投与し、 投与後 60分間静置 (絶水) し、 その後、 上記選抜試験と同一のプロ トコルにて試験を行い、 遊 泳時間を測定した。 結果を図 5に示す。 テアニンの投与量は、 公比約 3で 0 • 2mg/k g、 0. 5mg/k g、 1. 5mg/k gとした。 各投与群の 初期値を表 1に示す。  [0062] In this study, selected mice (8 animals in each group) were used, and each mouse was fasted overnight (about 15 hours), then theanine or water was administered, and then left still for 60 minutes after After that, the test was performed using the same protocol as the above selection test, and the swimming time was measured. The results are shown in FIG. The doses of theanine were 0 • 2 mg / kg, 0.5 mg / kg, and 1.5 mg / kg at a common ratio of about 3. Table 1 shows the initial values for each treatment group.
[0063] [表 1]  [0063] [Table 1]
(初期値)
Figure imgf000017_0001
(default value)
Figure imgf000017_0001
[0064] (結果) [0064] (Result)
全てのテアニン投与群で遊泳時間の延長が認められた。 この結果から、 テ ァニンは疲労時以外でも持久力を向上させることが分かった。 また、 その効 果は少なくとも 0. 2 m g/ k g以上で発揮されることも分かった。  In all theanine administration groups, the swimming time was prolonged. The results indicate that theanine improves endurance even when not fatigued. It was also found that the effect was exhibited at least 0.2 mg / kg or more.
[0065] (実施例 5) : テアニンの身体疲労軽減作用 [0065] (Example 5): Theanine reduces body fatigue
テアニンの身体疲労軽減作用を強制歩行による疲労負荷実験により調べた  The fatigue reduction effect of theanine was investigated by fatigue load experiment by forced walking
[0066] 実験には雄マウス CD F 1 (6週齢、 5匹) を用いた。 テアニンは、 L— テアニンを純水に溶解してテアニン濃度 0. 05mg/m l、 0. 5mg/ m I、 5. Omg/m Iのテアニン溶液を調製し、 試料とした。 [0066] Male mice CD F 1 (6 weeks old, 5 mice) were used in the experiment. For theanine, L-theanine was dissolved in pure water to prepare theanine solutions with theanine concentrations of 0.05 mg / ml, 0.5 mg / ml, and 5. Omg / ml, and used as samples.
[0067] 1週間のトレーニング後、 選抜試験を行った。 選抜試験では、 1分間に 1 5回転する速度(以下 1 5 r pmと記す)で 90分間強制歩行させた後、 90 分間の自発運動量を測定した。 この選抜試験を 1個体につき 2回行った。 選 抜基準は以下の条件を満たすものとした。 [0067] After one week of training, a selection test was conducted. In the selection test, after 90 minutes of forced walking at a speed of 15 revolutions per minute (hereinafter referred to as 15 rpm), 90 The amount of locomotor activity per minute was measured. This selection test was conducted twice per animal. The selection criteria satisfy the following conditions.
(1) 2回の運動量の平均が全体の平均土分散の範囲内に入っている。  (1) The average of the two momentums is within the overall average soil dispersion.
(2) 2回の運動量の差の絶対値が全体の分散より小さい。  (2) The absolute value of the difference between the two momentum is smaller than the total variance.
[0068] 本試験では選抜された個体 (各群 5匹) を対象として行い、 強制的にテア ニン又は水を経口投与 (5m L/k g) させた後、 直ちに 1 5 r pmの速度 で 45分間強制歩行させ、 再びテアニン又は水を強制経口投与 (5m L/k g) させ、 次いで 1 5 r pmの速度で 45分間の強制歩行を行わせた。 強制 歩行終了後、 90分間の自発運動量を測定した。 実験手順の概要を図 6に示 し、 初期値を表 2に示すと共に、 各投与群毎の自発運動量 (回) を図 7に、 テアニン投与量に対する各投与群毎の自発運動量を図 8に示した。 なお、 投 与試料としてのテアニンは、 公比 1 0で 0. 5mg/k g、 5. Omg/k g、 50mg/k gとし 7"二。  [0068] In this study, selected individuals (5 animals per group) were used as subjects, and theanine or water was forcibly administered orally (5 ml / kg), and then immediately at a rate of 15 rpm. Forced walking was performed for 1 minute, then theanine or water was again administered by oral gavage (5 mL / kg), and then forced walking was performed at a rate of 15 rpm for 45 minutes. Spontaneous exercise was measured for 90 minutes after forced walking. The outline of the experimental procedure is shown in Fig. 6, the initial values are shown in Table 2, the spontaneous exercise amount (times) for each administration group is shown in Fig. 7, and the spontaneous exercise amount in each administration group with respect to the theanine dose is shown in Fig. 8. Indicated. Theanine as the sample to be applied is 0.5 mg / kg at a common ratio of 10 and 5. Omg / kg, 50 mg / kg 7 ”
[0069] [表 2]  [0069] [Table 2]
(初期値)
Figure imgf000018_0001
(default value)
Figure imgf000018_0001
(平均士 S.D.) (Average person S.D.)
[0070] (結果) [0070] (Result)
全てのテアニン投与群で自発運動量が増加した。 このことから、 テアニン 投与量が少なくとも 50mg/k gまでは身体疲労軽減に有効であることが 明らかとなった。 この結果から、 テアニンの有効投与量を算出すると、 0. 1〜 1 00mg/k g、 ヒト換算では 6〜600 Om g (6 O k gとして) であることが分かった。  Spontaneous exercise increased in all theanine administration groups. From this, it was revealed that the theanine dose up to 50 mg / kg is effective in reducing physical fatigue. From this result, it was found that the effective dose of theanine was calculated to be 0.1 to 100 mg / kg, and 6 to 600 Omg (as 6 Okg) in human terms.
[0071] (実施例 6) : テアニン摂取による身体疲労軽減作用 [0071] (Example 6): Reducing body fatigue by ingestion of theanine
テアニンの摂取による身体疲労軽減効果を検討した。 身体疲労軽減の評価に は、 血液中の疲労負荷により上昇する成分の分析及び呼気ガス分析を行った  The effects of theanine intake on body fatigue were examined. For evaluation of body fatigue reduction, analysis of components that rise due to fatigue load in blood and breath gas analysis were performed.
[0072] 試験飲料として、 (1 ) ドリンク 1 (プラセボ) 、 (2) ドリンク 2 (テア ニン低容量 3 Omgン 200m I ) 、 (3) ドリンク 3 (テアニン高容量 1 5 Omg/2 O Om l ) 、 (4) ドリンク 4 (カテキン 1 00 m gZ200 m I ) を調製した。 ' [0072] As test beverages, (1) drink 1 (placebo), (2) drink 2 (tea (3) Drink 3 (Theanine high capacity 15 Omg / 2 O Oml), (4) Drink 4 (Catechin 100 mg Zm200 ml). '
[0073] 健康な男子大学生 1 2名 (平均年齢 20. 0±0. 9歳) を被験者とし、 上記飲料を試験 1週間前より 1日 2本 (朝.夕) 摂取させた。 試験当日には 、 運動負荷試験の前後に測定を行った。 運動負荷試験の前後には、 自覚症状 (VAS) 、 呼気ガス分析 (AT値等) 、 血中成分 ( 酸値、 総ケトン体等 [0073] Twelve healthy male university students (average age 20. 0 ± 0. 9 years old) were subjects, and the above beverages were ingested two times a day (morning and evening) one week before the test. On the day of the test, measurements were taken before and after the exercise test. Before and after exercise test, subjective symptoms (VAS), expired gas analysis (AT value, etc.), blood components (acid value, total ketone body, etc.)
) を測定した。 なお、 試験当日のスケジュールを図示すると以下の通 yであ る。 ) Was measured. The schedule for the day of the test is shown below.
[0074] [表 3]  [0074] [Table 3]
被験者 :健康な H子大^: 12名 (平均 Φ齢" 20.0±0.9歳)  Subjects: Healthy H child large ^: 12 (average Φ age 20.0 ± 0.9 years)
試験飲料 : drinkl (プラセボ) .  Test drink: drinkl (placebo).
drink2 (テア:ン低用 fi3Qmg/200ml)  drink2 (tea: low for fi3Qmg / 200ml)
. drink3 (テア =ン高用 fi 0mg/200ml)  drink3 (Thea high for fi 0mg / 200ml)
driuk4 (カテキン lOOmgteOOml)  driuk4 (catechin lOOmgteOOml)
※上 15飲科を試験当曰 1週問前より 1曰 2本(朝 夕) OTlさせた * Top 15 drinking courses were given OTl for 1 to 2 bottles (morning and evening) from the week before the test.
4群クロスォ一バ一  4 groups crossover
[00753
Figure imgf000019_0001
テアニン低用 量及びテアニン高用量の血中乳酸値は減少した。 近年では乳酸は疲労時の重 要な因子であることが報告されていることから、 実施例で認められた乳酸値 の減少は乳酸が疲労の回復に寄与した結果であると考え れる。
[00753
Figure imgf000019_0001
Blood lactate levels at low and high theanine doses decreased. In recent years, it has been reported that lactic acid is an important factor during fatigue, so the decrease in lactic acid levels observed in the examples is thought to be the result of lactic acid contributing to recovery from fatigue.
[0076] 図 9に 1週間各試験飲料摂取後に測定しだ AT値を示した。 テアニン低用量 及び高用量摂取群において A T値の上昇が認められ、 有酸素運動で行える運 '動強度が上昇した。  [0076] FIG. 9 shows AT values measured after ingestion of each test beverage for one week. In the theanine low-dose and high-dose intake groups, an increase in AT value was observed, and the exercise intensity that can be achieved by aerobic exercise increased.
[0077] 図 1 0には多段階運動負荷試験前後の血中乳酸値 (デルダ値) を示した。 テ ァニン低用量及びテアニン高用量の血中乳酸値は減少した。 近年では乳酸は 疲労時の重要な因宇であるこどが報告されていることから、 実施例で認めら れた乳酸値の減少は乳酸が疲労の回復に寄与した結果であると考えられる。  [0077] FIG. 10 shows the blood lactate level (Delda value) before and after the multi-stage exercise test. Blood lactate levels at low and high theanine doses decreased. In recent years, it has been reported that lactic acid is an important cause of fatigue, so the decrease in lactic acid levels observed in the examples is thought to be the result of lactic acid contributing to recovery from fatigue.
[0078] (実施例 7) :成長ホルモン分泌作用及び血糖値上昇作用 (Example 7): Growth hormone secretion action and blood glucose level raising action
差替え用紙 (規則 26) (実験動物及び飼育条件) Replacement paper (Rule 26) (Experimental animals and rearing conditions)
Wistar系雄性ラット (静岡実験動物) を 7週齢 (約 250 g) で購入し、 1 週間予備飼育した後、 実験に供した。 動物舎は、 室温 24±0. 5°C、 湿度 55±5%、 明暗周期(明期 7 : 00〜1 9 : 00)の飼育室内で管理され、 水及び餌 (MF、 オリエンタル酵母社製) を自由に摂取させた。  Wistar male rats (Shizuoka experimental animals) were purchased at 7 weeks of age (approximately 250 g), preliminarily raised for one week, and then subjected to experiments. The animal house is managed in a breeding room with a room temperature of 24 ± 0.5 ° C, humidity of 55 ± 5%, and a light / dark cycle (between 7:00 and 19:00). Water and food (MF, manufactured by Oriental Yeast Co., Ltd.) ).
[0079] (海馬局所投与と浸透圧ポンプの埋め込み手術) [0079] (Local hippocampal administration and osmotic pump implantation)
ペントバルビタール麻酔下でラット脳定位固定装置にラットを固定し、 頭骨 を露出させた。 前頭部及び後頭部の頭蓋骨にアンカービスを埋め込み、 ラッ ト脳図譜 (G. Paxinos and C. Watson著)に従って海馬上の頭蓋に小穴を開け た。 薬物注入力ニューレの先端は、 ブレグマ (bregma) から P = _5. 5、 L = ±4. 5、 V= 5. Ommに位置していた。 両側の海馬に揷入した力二 ユーレとアンカービスは歯科用セメントで頭蓋に固定し、 背部皮下に埋め込 んだ浸透圧ポンプ (Alzet  Under anesthesia with pentobarbital, the rat was fixed to a rat stereotaxic apparatus and the skull was exposed. Anchor screws were embedded in the skulls in the frontal and occipital areas, and small holes were made in the skull on the hippocampus according to the rat brain chart (by G. Paxinos and C. Watson). The tip of the drug injection neulet was located from the bregma at P = _5.5, L = ± 4.5, V = 5. Omm. The osmotic pump (Alzet), which was fixed in the skull with dental cement and embedded in the back of the back, was inserted into the hippocampus on both sides.
2002 Durect社製) は、 ビニールチューブで連結した。 浸透圧ポンプの fill v olumeは 21 4 μ. Iで pumping rateは 0. 5 μ. I / h 「であった。  2002 Durect) were connected with a vinyl tube. The fill v olume of the osmotic pump was 21 4 μ. I, and the pumping rate was 0.5 μ. I / h.
[0080] (薬物の調整と投与量) [0080] (Drug adjustment and dosage)
テアニン(伊藤園社製)を生理食塩水に溶解し、 ミリポアフィルター (Millex- GS、 ミリポア社製) にて濾過した後、 浸透圧ポンプに充填した。 薬物濃度は 、 0. 1 u M 1 M及び 1 0;UMであり、 対照群として生理食塩水を投与 した。  Theanine (manufactured by ITO EN) was dissolved in physiological saline, filtered through a Millipore filter (Millex-GS, manufactured by Millipore), and then filled into an osmotic pump. The drug concentrations were 0.1 u M 1 M and 10; UM, and physiological saline was administered as a control group.
[0081] (絶食によるストレス負荷)  [0081] (Stress load due to fasting)
ラット海馬にテアニンの局所投与を開始して第 9日目から約 36時間にわた つて絶食させた。 その後、 採血して得た血液を分析に供した。  The rat hippocampus was started with local theanine administration and fasted for about 36 hours from day 9. Thereafter, blood obtained by blood collection was used for analysis.
[0082] (血糖値及び成長ホルモンの測定) [0082] (Measurement of blood glucose level and growth hormone)
屠殺時の血糖値は、 メディセーフチップ (MS-FG25, TERUMO Co. ) を装着した メデイセ一フリーダ一 (GR-101, TERUMO  The blood sugar level at the time of slaughter was measured by the Medice Freeder (GR-101, TERUMO) equipped with a Medisafe chip (MS-FG25, TERUMO Co.).
Co. ) で直接測定した。 成長ホルモンは S R L株式会社に依頼し測定した。 S RL株式会社で測定されている方法は、 非特許文献 (石渡尚子ら, ホルモン と臨床, 38 (6) , 601-606) にも記載されているが、 抗体をアイソトープで 標識する i mmunorad i ometr i c Co.). Growth hormone was measured by SRL. Non-patent literature (Naoko Ishiwata et al., Hormone) And clinical studies, 38 (6), 601-606), which label antibodies with isotopes.
assay ( I RMA) ものである。  assay (IRMA).
[0083] (結果) [0083] (Result)
1 ; UM又は 1 O Mのテアニンを海馬に直接投与することにより成長ホルモ ンの分泌は促進され、 特に 1 ; UMで顕著であった。 また、 血糖値についても 調べたところ、 テアニンを投与することで血糖値を上昇させる効果が認めら れた。 血漿中の成長ホルモンの分泌量を調べた結果を図 1 1に、 血糖値の分 泌量を調べた結果を図 1 2にそれぞれ示す。  1; UM or 1 O M theanine was administered directly to the hippocampus to promote growth hormone secretion, especially 1; In addition, the blood glucose level was also examined, and it was found that administration of theanine had the effect of increasing the blood glucose level. Fig. 11 shows the results of examining the amount of growth hormone secreted in plasma, and Fig. 12 shows the results of examining the amount of blood glucose produced.
図面の簡単な説明  Brief Description of Drawings
[0084] [図 1]テアニンの脂質利用促進試験 (実施例 1 ) において、 相対運動量につい て、 コントロール投与群 (DW) とテアニン投与群 (theanine) とを比較し たグラフである。  [0084] Fig. 1 is a graph comparing the control exercise group (DW) and the theanine administration group (theanine) regarding the relative momentum in the lipid utilization promotion test of theanine (Example 1).
[図 2]テアニンの脂質利用促進試験 (実施例 1 ) において、 血中脂肪酸濃度に ついて、 コントロール投与群 (DW) とテアニン投与群 (theanine) とを比 較したグラフである。  FIG. 2 is a graph comparing the control fatty acid group (DW) and the theanine administration group (theanine) with respect to blood fatty acid concentration in the lipid utilization promotion test for theanine (Example 1).
[図 3]テアニンの身体疲労軽減■持久力向上試験 (実施例 2) において、 回転 数の減少数 (回) について、 コントロール投与群 (水投与群) とテアニン投 与群とを比較したグラフである。  [Fig. 3] Reduction of the physical fatigue of theanine ■ In the endurance improvement test (Example 2), the number of rotation reduction (times) is a graph comparing the control administration group (water administration group) and the theanine administration group. is there.
[図 4]テアニンの有効濃度確認試験 (実施例 3) において、 回転数の減少数 ( 回) を各投与群毎に示したグラフである。  FIG. 4 is a graph showing the number of reductions in rotations (times) for each administration group in the effective concentration confirmation test for theanine (Example 3).
[図 5]テアニンの持久力向上試験 (実施例 4) において、 遊泳時間 (秒) を各 投与群毎に示したグラフである。  FIG. 5 is a graph showing swimming time (seconds) for each administration group in the endurance improvement test (Example 4) of theanine.
[図 6]テアニンの身体疲労軽減作用 (実施例 5) における実験手順の概要を示 した図である。  FIG. 6 is a diagram showing an outline of an experimental procedure in the body fatigue reducing action (Example 5) of theanine.
[図 7]テアニンの身体疲労軽減作用 (実施例 5) において、 各投与群毎の自発 運動量 (回) を示したグラフである。  FIG. 7 is a graph showing the amount of spontaneous exercise (times) for each administration group in the body fatigue alleviating action (Example 5) of theanine.
[図 8]テアニンの身体疲労軽減作用 (実施例 5) において、 テアニン投与量に 対する各投与群毎の自発運動量を示したグラフである。 [Fig. 8] In the body fatigue alleviation effect (Example 5) of theanine, It is the graph which showed the spontaneous exercise amount for every administration group with respect to.
[図 9] 1週間各試験飲料摂取後に測定した A T値を示す図である。 1週間各試 験飲料摂取後に測定した A T値を示した。 テアニン低用量及び高用量摂取群 において A T値の上昇が認められ、 有酸素運動で行える運動強度が上昇した  FIG. 9 is a diagram showing AT values measured after intake of each test beverage for one week. The AT values measured after ingestion of each test drink for 1 week are shown. An increase in AT was observed in the low and high dose theanine groups, and the exercise intensity that can be achieved with aerobic exercise increased.
[図 10]多段階運動負荷試験による血中乳酸値の変化を示す図である。 運動負 荷にはトレッドミルを用いた。 運動開始時は回転速度 0 . 5 k m/ h、 傾斜 0 %とし、 3 0秒毎に回転速度を 0 . 5 k m/ h、 傾斜を 0 . 5 %ずつ増加 させる多段階運動負荷試験を実施した。 FIG. 10 is a graph showing changes in blood lactic acid levels by a multi-stage exercise load test. A treadmill was used for the exercise load. At the start of exercise, a multi-stage exercise load test was conducted with a rotational speed of 0.5 km / h and a slope of 0%, and the rotational speed was increased by 0.5 km / h and the slope by 0.5% every 30 seconds. .
[図 1 1 ]血漿中の成長ホルモンの分泌量を調べた結果を示す図である。  FIG. 1 1 is a diagram showing the results of examining the amount of growth hormone secreted in plasma.
[図 12]血糖値の分泌量を調べた結果を示す図である。 FIG. 12 is a view showing the results of examining the secretion amount of blood glucose level.

Claims

請求の範囲 The scope of the claims
[1 ] テアニンを有効成分とする代謝促進組成物。  [1] A metabolism promoting composition containing theanine as an active ingredient.
[2] テアニンの脂質利用促進作用により代謝促進作用が生じることを特徴とす る請求項 1記載の代謝促進組成物。  [2] The metabolism promoting composition according to [1], wherein the theanine has a lipid utilization promoting action to produce a metabolic promoting action.
[3] 代謝促進作用が、 持久力向上、 成長ホルモン分泌促進、 血糖値上昇、 脂肪 燃焼、 有酸素運動時の疲労軽減、 嫌気性代謝閾値の上昇、 血中乳酸蓄積の軽 減、 抗疲労からなる群から選ばれるものであることを特徴とする請求項 1又 は 2記載の代謝促進組成物。 [3] Metabolic promotion effects from endurance improvement, growth hormone secretion promotion, blood sugar level increase, fat burning, fatigue reduction during aerobic exercise, anaerobic metabolic threshold increase, blood lactate accumulation reduction, anti-fatigue 3. The composition for promoting metabolism according to claim 1, wherein the composition is selected from the group consisting of:
[4] 体重 1 k g当たり 0 . 5〜5 m g / k gのテアニンを含有することを特徴 とする請求項 1〜 3のいずれか記載の代謝促進組成物。 [4] The metabolism promoting composition according to any one of [1] to [3], comprising 0.5 to 5 mg / kg of theanine per 1 kg of body weight.
[5] テアニンを 6〜6 0 0 O m g含有することを特徴とする請求項 1〜4いず れか記載の代謝促進組成物。 [5] The metabolism promoting composition according to any one of [1] to [4], which contains 6 to 600 mg of theanine.
[6] 請求項 1〜 5のいずれか記載の代謝促進組成物を配合した飲食物。 [6] A food or drink comprising the metabolism promoting composition according to any one of claims 1 to 5.
[7] 請求項 1〜 6のいずれか記載の代謝促進組成物を経口摂取することを特徴 とする代謝促進方法。 [7] A method for promoting metabolism, comprising orally ingesting the composition for promoting metabolism according to any one of [1] to [6].
[8] 代謝促進作用が、 脂質利用促進、 成長ホルモン分泌促進、 血糖値上昇、 脂 肪燃焼、 有酸素運動時の疲労軽減、 嫌気性代謝閾値の上昇、 血中乳酸蓄積の 軽減、 抗疲労からなる群から選ばれる 1又は 2以上の作用であることを特徴 とする請求項 7記載の代謝促進方法。  [8] Metabolic promotion effects from lipid utilization promotion, growth hormone secretion promotion, blood sugar level increase, fat burning, fatigue reduction during aerobic exercise, anaerobic metabolic threshold increase, blood lactate accumulation reduction, anti-fatigue 8. The method for promoting metabolism according to claim 7, wherein the action is one or more selected from the group consisting of:
[9] テアニンの投与量が、 1回の投与につき体重 1 k g当たり 0 . 5〜5 m g / k gであることを特徴とする請求項 7又は 8記載の代謝促進方法。  9. The method of promoting metabolism according to claim 7 or 8, wherein the theanine is administered in an amount of 0.5 to 5 mg / kg body weight per kilogram per administration.
PCT/JP2007/000804 2006-07-28 2007-07-27 Composition for stimulation of metabolism WO2008012952A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2006205967A JP2008031080A (en) 2006-07-28 2006-07-28 Lipid utilization-promoting composition
JP2006-205967 2006-07-28
JP2006-253686 2006-09-20
JP2006253686A JP2008074733A (en) 2006-09-20 2006-09-20 Composition for improving endurance
JP2006-287105 2006-10-23
JP2006287105A JP4709120B2 (en) 2006-10-23 2006-10-23 Composition for promoting growth hormone secretion

Publications (1)

Publication Number Publication Date
WO2008012952A1 true WO2008012952A1 (en) 2008-01-31

Family

ID=38981268

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/000804 WO2008012952A1 (en) 2006-07-28 2007-07-27 Composition for stimulation of metabolism

Country Status (1)

Country Link
WO (1) WO2008012952A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945655B2 (en) 2007-07-10 2015-02-03 Conopco, Inc. Stable and consumable compositions

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09100230A (en) * 1995-10-03 1997-04-15 Itouen:Kk Excitation promoting agent
JP2001187736A (en) * 1999-10-20 2001-07-10 Ito En Ltd Nutritive analeptic and nutritive analeptic drink
JP2001316256A (en) * 2000-04-28 2001-11-13 Taiyo Kagaku Co Ltd Composition for ameliorating blood flow
JP2002370979A (en) * 2001-06-11 2002-12-24 Taiyo Kagaku Co Ltd Composition for improving mental concentration
WO2004093865A1 (en) * 2003-04-24 2004-11-04 Amorepacific Corporation Composition for slimming
WO2005107734A1 (en) * 2004-05-06 2005-11-17 Taiyokagaku Co., Ltd. Alcohol metabolism accelerating composition, and food or drink containing the composition
JP2006077027A (en) * 1999-10-20 2006-03-23 Ito En Ltd Nutritive analeptic and nutritive analeptic drink

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09100230A (en) * 1995-10-03 1997-04-15 Itouen:Kk Excitation promoting agent
JP2001187736A (en) * 1999-10-20 2001-07-10 Ito En Ltd Nutritive analeptic and nutritive analeptic drink
JP2006077027A (en) * 1999-10-20 2006-03-23 Ito En Ltd Nutritive analeptic and nutritive analeptic drink
JP2001316256A (en) * 2000-04-28 2001-11-13 Taiyo Kagaku Co Ltd Composition for ameliorating blood flow
JP2002370979A (en) * 2001-06-11 2002-12-24 Taiyo Kagaku Co Ltd Composition for improving mental concentration
WO2004093865A1 (en) * 2003-04-24 2004-11-04 Amorepacific Corporation Composition for slimming
WO2005107734A1 (en) * 2004-05-06 2005-11-17 Taiyokagaku Co., Ltd. Alcohol metabolism accelerating composition, and food or drink containing the composition

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945655B2 (en) 2007-07-10 2015-02-03 Conopco, Inc. Stable and consumable compositions

Similar Documents

Publication Publication Date Title
JP3907964B2 (en) Mental fatigue reducing composition, concentration maintenance enhancing composition and mental vitality maintenance enhancing composition
EP2050444B1 (en) Fatigue-reducing agent
WO2001087291A1 (en) Compositions normalizing circadian rhythm
EP2532351B1 (en) Agent for improving motility function
CN104922115A (en) Anti-fatigue agent comprising amino acid composition
EP3115047B1 (en) Debility preventative
KR100481379B1 (en) Food composition for lowering body fat content and improving body composition and method therefor
CN102273581A (en) Compound sweetener with high sweetness
JP3433917B2 (en) Nutritional composition for enhancing body protein accumulation efficiency
JP2005213185A (en) Energy-supplementary and anti-fatigue food and beverage
JP5394644B2 (en) Muscle enhancer containing asperroside or its analog
WO2008012952A1 (en) Composition for stimulation of metabolism
JP4163801B2 (en) Alcohol metabolism promoting agent
JP2008031080A (en) Lipid utilization-promoting composition
CA2757351C (en) Anti-mental fatigue drug
JP2001048794A (en) Health food and medicinal composition which contain mixture of powder originated from leaf of mulberry and powder originated from oyster and is used for treating niddm
JP6881984B2 (en) Binge eating inhibitor
JP4709120B2 (en) Composition for promoting growth hormone secretion
JP2012180331A (en) Oral ingestion medicine for inducement of early recovery of muscle damage
JP2000302677A (en) Medicine and food/feed composition having improving action on carnitine self production ability
JP2008074733A (en) Composition for improving endurance
JP2014051459A (en) Fat metabolism enhancer
JP2021016375A (en) Aerobic motor function improver, food composition for aerobic motor function improvement, and pharmaceutical composition for aerobic motor function improvement
JP2023160181A (en) Agent for increasing level of ornithine in blood
KR20240088908A (en) AMPK activator, motor function enhancer, muscle endurance enhancer and muscle atrophy inhibitor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07790298

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07790298

Country of ref document: EP

Kind code of ref document: A1